https://trial.medpath.com/news/tevogen-ceo-expresses-gratitude-for-unprecedented-public-globenewswire 2024-10-19T02:50:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tevogen-ceo-expresses-gratitude-for-unprecedented-public-globenewswire 2024-10-19T02:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/tranexamic-acid-for-reduction-of-intra-and-postoperative-transfusion-requirements-in-trials 2024-10-19T02:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tranexamic-acid-for-reduction-of-intra-and-postoperative-transfusion-requirements-in-trials 2024-10-19T02:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/international-medical-graduates-vital-to-addressing-u-s-oncology-workforce-shortage 2024-10-19T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/international-medical-graduates-vital-to-addressing-u-s-oncology-workforce-shortage 2024-10-19T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/supernus-depression-drug-improved-symptoms-in-two-hours-in-phase-iia-study 2024-10-19T00:29:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/supernus-depression-drug-improved-symptoms-in-two-hours-in-phase-iia-study 2024-10-19T00:29:04+00:00 weekly 0.7 https://trial.medpath.com/news/botox-r-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe 2024-10-19T00:13:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/botox-r-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe 2024-10-19T00:13:25+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-persistence-with-ocrelizumab-in-multiple-sclerosis-patients 2024-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-persistence-with-ocrelizumab-in-multiple-sclerosis-patients 2024-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bra-lliant-breakthrough-ultrasound-bra-detects-breast-cancer-at-home-wilx 2024-10-18T22:48:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bra-lliant-breakthrough-ultrasound-bra-detects-breast-cancer-at-home-wilx 2024-10-18T22:48:25+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-wins-fda-nods-for-nav-enabled-farapulse-catheter-software-massdevice 2024-10-18T22:28:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-wins-fda-nods-for-nav-enabled-farapulse-catheter-software-massdevice 2024-10-18T22:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-premature-aging-disease-treatment-mirage-news 2024-10-18T22:16:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-premature-aging-disease-treatment-mirage-news 2024-10-18T22:16:49+00:00 weekly 0.7 https://trial.medpath.com/news/tiziana-life-sciences-advances-with-promising-drug-trials-tipranks-com 2024-10-18T21:29:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiziana-life-sciences-advances-with-promising-drug-trials-tipranks-com 2024-10-18T21:29:48+00:00 weekly 0.7 https://trial.medpath.com/news/ep-104iar-phase-2-data-shows-potential-for-knee-osteoarthritis-pain-hcplive 2024-10-18T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ep-104iar-phase-2-data-shows-potential-for-knee-osteoarthritis-pain-hcplive 2024-10-18T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/press-releases-friday-oct-18-2024-genentech 2024-10-18T21:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-releases-friday-oct-18-2024-genentech 2024-10-18T21:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunotherapy-for-liver-cancer-shrinking-tumors-growing-responses 2024-10-18T20:59:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-immunotherapy-for-liver-cancer-shrinking-tumors-growing-responses 2024-10-18T20:59:28+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-at-fda-new-guidances-address-cancer-pros-neurodevelopmental-safety 2024-10-18T20:42:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-week-at-fda-new-guidances-address-cancer-pros-neurodevelopmental-safety 2024-10-18T20:42:44+00:00 weekly 0.7 https://trial.medpath.com/news/selinexor-receives-approval-in-south-korea-for-multiple-myeloma-onclive 2024-10-18T19:55:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/selinexor-receives-approval-in-south-korea-for-multiple-myeloma-onclive 2024-10-18T19:55:24+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-october-18-2024 2024-10-18T19:07:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-october-18-2024 2024-10-18T19:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/successful-special-procedure-study-conduct-cerebrospinal-fluid-csf-and-concurrent 2024-10-18T19:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/successful-special-procedure-study-conduct-cerebrospinal-fluid-csf-and-concurrent 2024-10-18T19:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/partnering-for-precision-in-an-ipf-study-securing-timely-deliverables-and-key-endpoints 2024-10-18T19:07:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/partnering-for-precision-in-an-ipf-study-securing-timely-deliverables-and-key-endpoints 2024-10-18T19:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pushes-back-decision-on-sotorasib-panitumumab-in-colorectal-cancer 2024-10-18T18:10:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-pushes-back-decision-on-sotorasib-panitumumab-in-colorectal-cancer 2024-10-18T18:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/botensilimab-plus-balstilimab-elicits-durable-responses-in-refractory-metastatic-sarcoma 2024-10-18T18:09:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/botensilimab-plus-balstilimab-elicits-durable-responses-in-refractory-metastatic-sarcoma 2024-10-18T18:09:57+00:00 weekly 0.7 https://trial.medpath.com/news/eu-may-approve-oxford-astrazeneca-vaccine-this-week-says-german-health-ministry-spokesman 2024-10-18T17:53:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-may-approve-oxford-astrazeneca-vaccine-this-week-says-german-health-ministry-spokesman 2024-10-18T17:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/cognivue-clarity-characterizes-mild-cognitive-impairment-and-alzheimer-s-disease-in-nature 2024-10-18T17:39:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cognivue-clarity-characterizes-mild-cognitive-impairment-and-alzheimer-s-disease-in-nature 2024-10-18T17:39:31+00:00 weekly 0.7 https://trial.medpath.com/news/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2024 2024-10-18T17:20:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2024 2024-10-18T17:20:22+00:00 weekly 0.7 https://trial.medpath.com/news/tme-pharma-reports-h1-2024-financial-results-and-provides-business-and-clinical-update 2024-10-18T16:44:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tme-pharma-reports-h1-2024-financial-results-and-provides-business-and-clinical-update 2024-10-18T16:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/autoantibodies-to-protein-s-may-explain-rare-cases-of-coagulopathy-following-covid-19-vaccination 2024-10-18T16:28:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autoantibodies-to-protein-s-may-explain-rare-cases-of-coagulopathy-following-covid-19-vaccination 2024-10-18T16:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/companies-to-watch-spinogenix-life-science-leader 2024-10-18T16:12:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/companies-to-watch-spinogenix-life-science-leader 2024-10-18T16:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/european-equities-close-mostly-higher-in-friday-trading-novo-nordisk-s-catalent-tradingview 2024-10-18T16:03:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-equities-close-mostly-higher-in-friday-trading-novo-nordisk-s-catalent-tradingview 2024-10-18T16:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-first-in-class-intracellular-checkpoint-inhibitor-of-dgk-and-z-stemming-from-phenotypic-screening 2024-10-18T15:48:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-first-in-class-intracellular-checkpoint-inhibitor-of-dgk-and-z-stemming-from-phenotypic-screening 2024-10-18T15:48:20+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-s-reign-over-the-drug-development-pipeline-continues-amcp-nexus-2024 2024-10-18T15:48:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-s-reign-over-the-drug-development-pipeline-continues-amcp-nexus-2024 2024-10-18T15:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/a-wechat-platform-program-wcpp-for-full-process-management-of-patients-with-cardiac-trials 2024-10-18T15:41:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-wechat-platform-program-wcpp-for-full-process-management-of-patients-with-cardiac-trials 2024-10-18T15:41:19+00:00 weekly 0.7 https://trial.medpath.com/news/time-to-sustained-recovery-among-outpatients-with-covid-19-receiving-montelukast-vs-placebo 2024-10-18T15:25:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/time-to-sustained-recovery-among-outpatients-with-covid-19-receiving-montelukast-vs-placebo 2024-10-18T15:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-several-medicines-in-october-biopharm-international 2024-10-18T15:24:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-recommends-several-medicines-in-october-biopharm-international 2024-10-18T15:24:19+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-rebuffed-again-by-ema-novartis-licenses-china-based-biotech-s-cancer-drug 2024-10-18T15:07:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-rebuffed-again-by-ema-novartis-licenses-china-based-biotech-s-cancer-drug 2024-10-18T15:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-bioresearch-monitoring-technical-specifications-document-to-help-you 2024-10-18T15:07:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-bioresearch-monitoring-technical-specifications-document-to-help-you 2024-10-18T15:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/the-francis-crick-institute-launches-a-new-project-aimed-at-understanding-immunotherapy-vwv 2024-10-18T14:57:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-francis-crick-institute-launches-a-new-project-aimed-at-understanding-immunotherapy-vwv 2024-10-18T14:57:56+00:00 weekly 0.7 https://trial.medpath.com/news/ucla-study-aims-to-develop-same-day-detection-of-cancer-cells-in-cerebrospinal-fluid 2024-10-18T14:56:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucla-study-aims-to-develop-same-day-detection-of-cancer-cells-in-cerebrospinal-fluid 2024-10-18T14:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/inotuzumab-ozogamicin-in-pediatric-patients-with-relapsed-or-refractory-b-cell-all 2024-10-18T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inotuzumab-ozogamicin-in-pediatric-patients-with-relapsed-or-refractory-b-cell-all 2024-10-18T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/endo-presents-data-at-the-american-society-of-podiatric-surgeons-asps-annual-surgical 2024-10-18T14:37:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endo-presents-data-at-the-american-society-of-podiatric-surgeons-asps-annual-surgical 2024-10-18T14:37:10+00:00 weekly 0.7 https://trial.medpath.com/news/repurposed-als-drug-shows-promise-against-aggressive-brain-tumors 2024-10-18T14:32:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repurposed-als-drug-shows-promise-against-aggressive-brain-tumors 2024-10-18T14:32:09+00:00 weekly 0.7 https://trial.medpath.com/news/new-fda-designations-may-jumpstart-gene-therapy-development 2024-10-18T14:22:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-fda-designations-may-jumpstart-gene-therapy-development 2024-10-18T14:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-anovo-system-for-abdominal-hernia-repair-the-jerusalem-post 2024-10-18T14:02:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-anovo-system-for-abdominal-hernia-repair-the-jerusalem-post 2024-10-18T14:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/ema-awards-prime-status-to-pentixapharm-s-ga68-pentixafor-webdisclosure 2024-10-18T14:02:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-awards-prime-status-to-pentixapharm-s-ga68-pentixafor-webdisclosure 2024-10-18T14:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-trial-results-of-novel-triple-combination-pill-for-hypertension-published-in-the-lancet 2024-10-18T13:46:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-trial-results-of-novel-triple-combination-pill-for-hypertension-published-in-the-lancet 2024-10-18T13:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-pharmaceuticals-to-present-data-at-the-2024-annual-scientific-meeting-of-the-biospace 2024-10-18T13:46:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalvista-pharmaceuticals-to-present-data-at-the-2024-annual-scientific-meeting-of-the-biospace 2024-10-18T13:46:05+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-biopharma-ltd-american-depositary-shares-each-representing-three-hundred 2024-10-18T13:45:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-fite-biopharma-ltd-american-depositary-shares-each-representing-three-hundred 2024-10-18T13:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/brown-glaberman-reviews-data-for-pik3ca-altered-metastatic-breast-cancer 2024-10-18T13:38:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brown-glaberman-reviews-data-for-pik3ca-altered-metastatic-breast-cancer 2024-10-18T13:38:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pushes-back-pdufa-dates-for-amgen-and-intercept-biospace 2024-10-18T13:26:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-pushes-back-pdufa-dates-for-amgen-and-intercept-biospace 2024-10-18T13:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/significant-positive-results-from-osteoarthritis-clinical-study-in-dogs-treated-with-piclidenoson 2024-10-18T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/significant-positive-results-from-osteoarthritis-clinical-study-in-dogs-treated-with-piclidenoson 2024-10-18T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/aao-2024-livionex-reports-positive-end-of-phase-2-meeting-with-fda-on-the-development 2024-10-18T13:07:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aao-2024-livionex-reports-positive-end-of-phase-2-meeting-with-fda-on-the-development 2024-10-18T13:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/cerus-corporation-announces-workshop-and-abstracts-at-the-2024-aabb-annual-meeting 2024-10-18T12:50:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerus-corporation-announces-workshop-and-abstracts-at-the-2024-aabb-annual-meeting 2024-10-18T12:50:44+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-announces-that-enrollment-in-its-adult-acute-kidney-injury-pivotal-trial-has 2024-10-18T12:47:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seastar-medical-announces-that-enrollment-in-its-adult-acute-kidney-injury-pivotal-trial-has 2024-10-18T12:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-provides-update-on-u-s-indication-for-trodelvy-r-in-metastatic-urothelial-cancer 2024-10-18T12:39:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-provides-update-on-u-s-indication-for-trodelvy-r-in-metastatic-urothelial-cancer 2024-10-18T12:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/msd-mulls-2025-26-launch-for-rsv-vaccine-after-phase-ii-iii-win 2024-10-18T12:27:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/msd-mulls-2025-26-launch-for-rsv-vaccine-after-phase-ii-iii-win 2024-10-18T12:27:12+00:00 weekly 0.7 https://trial.medpath.com/news/safety-data-help-affirm-adjuvant-alectinib-as-a-new-soc-in-alk-nsclc-onclive 2024-10-18T12:20:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-data-help-affirm-adjuvant-alectinib-as-a-new-soc-in-alk-nsclc-onclive 2024-10-18T12:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/amylyx-s-amx0035-shows-promise-in-phase-ii-wolfram-syndrome-trial 2024-10-18T11:19:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amylyx-s-amx0035-shows-promise-in-phase-ii-wolfram-syndrome-trial 2024-10-18T11:19:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-declares-iv-fluid-shortage-following-hurricane-impact-on-baxter-facilities 2024-10-18T11:12:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-declares-iv-fluid-shortage-following-hurricane-impact-on-baxter-facilities 2024-10-18T11:12:13+00:00 weekly 0.7 https://trial.medpath.com/news/lanova-medicines-announces-initiation-of-phase-1-clinical-trial-of-anti-pd-1-vegf-biospace 2024-10-18T11:01:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lanova-medicines-announces-initiation-of-phase-1-clinical-trial-of-anti-pd-1-vegf-biospace 2024-10-18T11:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/low-dose-bel-sar-shows-promising-safety-efficacy-in-nmibc-in-phase-1-study 2024-10-18T10:20:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-dose-bel-sar-shows-promising-safety-efficacy-in-nmibc-in-phase-1-study 2024-10-18T10:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-confirms-rsv-vaccine-s-protective-power-for-seniors 2024-10-18T10:06:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-study-confirms-rsv-vaccine-s-protective-power-for-seniors 2024-10-18T10:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/evergreen-theragnostics-opens-cck2-view-a-phase-ii-small-cell-lung-cancer-clinical-trial 2024-10-18T10:02:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evergreen-theragnostics-opens-cck2-view-a-phase-ii-small-cell-lung-cancer-clinical-trial 2024-10-18T10:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/translarna-ema-re-confirms-non-renewal-of-authorisation-of-duchenne-muscular-dystrophy 2024-10-18T10:01:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/translarna-ema-re-confirms-non-renewal-of-authorisation-of-duchenne-muscular-dystrophy 2024-10-18T10:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-approval-of-novo-nordisk-hemophilia-drug-medwatch 2024-10-18T09:57:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-approval-of-novo-nordisk-hemophilia-drug-medwatch 2024-10-18T09:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/response-begins-enrolment-for-trial-of-rdx-002-for-weight-management 2024-10-18T09:47:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/response-begins-enrolment-for-trial-of-rdx-002-for-weight-management 2024-10-18T09:47:33+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-a-s-alhemo-r-recommended-for-european-approval-globenewswire 2024-10-18T09:38:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-a-s-alhemo-r-recommended-for-european-approval-globenewswire 2024-10-18T09:38:20+00:00 weekly 0.7 https://trial.medpath.com/news/risk-stratification-and-population-health-key-to-revolutionizing-ckd-care-management 2024-10-18T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risk-stratification-and-population-health-key-to-revolutionizing-ckd-care-management 2024-10-18T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-phase-clinical-trials-for-the-development-of-novel-immunotherapeutic-anti-cancer-agents 2024-10-18T08:31:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-phase-clinical-trials-for-the-development-of-novel-immunotherapeutic-anti-cancer-agents 2024-10-18T08:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/social-determinants-create-stark-disparities-in-type-2-diabetes-care-and-outcomes 2024-10-18T08:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/social-determinants-create-stark-disparities-in-type-2-diabetes-care-and-outcomes 2024-10-18T08:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-weekly-us-225-million-investment-towards-world-class-research-institute 2024-10-18T07:51:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-therapy-weekly-us-225-million-investment-towards-world-class-research-institute 2024-10-18T07:51:38+00:00 weekly 0.7 https://trial.medpath.com/news/landmark-unmc-research-studies-abc-s-of-icu-care-newsroom 2024-10-18T07:11:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/landmark-unmc-research-studies-abc-s-of-icu-care-newsroom 2024-10-18T07:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/nitrogen-dioxide-air-pollution-linked-to-21-higher-ovarian-cancer-risk-in-us-study 2024-10-18T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nitrogen-dioxide-air-pollution-linked-to-21-higher-ovarian-cancer-risk-in-us-study 2024-10-18T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vaccine-against-the-mers-coronavirus-tested-as-safe-and-effective-in-phase-ib-clinical-trial 2024-10-18T06:59:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaccine-against-the-mers-coronavirus-tested-as-safe-and-effective-in-phase-ib-clinical-trial 2024-10-18T06:59:47+00:00 weekly 0.7 https://trial.medpath.com/news/ondine-biomedical-steriwave-receives-uae-regulatory-approval-research-tree 2024-10-18T06:17:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ondine-biomedical-steriwave-receives-uae-regulatory-approval-research-tree 2024-10-18T06:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-clinical-trials-receive-22m-funding-boost-hospital-healthcare 2024-10-18T05:49:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-clinical-trials-receive-22m-funding-boost-hospital-healthcare 2024-10-18T05:49:28+00:00 weekly 0.7 https://trial.medpath.com/news/machine-learning-based-model-for-cd4-conventional-t-cell-genes-to-predict-survival-and 2024-10-18T05:08:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/machine-learning-based-model-for-cd4-conventional-t-cell-genes-to-predict-survival-and 2024-10-18T05:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-trial-of-psma-pet-ct-versus-planar-bone-scan-and-ct-in-prostate-cancer-patients-nature 2024-10-18T03:56:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-trial-of-psma-pet-ct-versus-planar-bone-scan-and-ct-in-prostate-cancer-patients-nature 2024-10-18T03:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/comparing-remimazolam-and-propofol-for-postoperative-anesthesia-satisf-dddt 2024-10-18T03:54:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparing-remimazolam-and-propofol-for-postoperative-anesthesia-satisf-dddt 2024-10-18T03:54:37+00:00 weekly 0.7 https://trial.medpath.com/news/inhalerx-procures-38-5m-in-funding-from-clendon-biotech-to-progress-inhaled-therapies 2024-10-18T03:25:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inhalerx-procures-38-5m-in-funding-from-clendon-biotech-to-progress-inhaled-therapies 2024-10-18T03:25:46+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-ezetimib-rifampin-may-increase-coproporphyrin-concentrations-in-healthy-patients 2024-10-18T01:24:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-ezetimib-rifampin-may-increase-coproporphyrin-concentrations-in-healthy-patients 2024-10-18T01:24:48+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-announces-plans-to-voluntarily-withdraw-the-u-s-accelerated-approval-for-trodelvy-in-metastatic-urothelial-cancer 2024-10-18T01:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-announces-plans-to-voluntarily-withdraw-the-u-s-accelerated-approval-for-trodelvy-in-metastatic-urothelial-cancer 2024-10-18T01:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/promising-growth-and-innovation-drive-buy-recommendation-for-rapport-therapeutics-inc 2024-10-18T00:36:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-growth-and-innovation-drive-buy-recommendation-for-rapport-therapeutics-inc 2024-10-18T00:36:20+00:00 weekly 0.7 https://trial.medpath.com/news/botox-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe-vertical-bands-connecting-the-jaw-and-neck-platysma-bands 2024-10-18T00:10:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/botox-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe-vertical-bands-connecting-the-jaw-and-neck-platysma-bands 2024-10-18T00:10:37+00:00 weekly 0.7 https://trial.medpath.com/news/unlearn-s-digital-twins-slash-pharma-trial-costs-by-millions-drug-discovery-and-development 2024-10-17T23:31:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unlearn-s-digital-twins-slash-pharma-trial-costs-by-millions-drug-discovery-and-development 2024-10-17T23:31:04+00:00 weekly 0.7 https://trial.medpath.com/news/nih-awards-acri-2-9-million-for-critical-cystic-fibrosis-therapy-research 2024-10-17T22:40:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-awards-acri-2-9-million-for-critical-cystic-fibrosis-therapy-research 2024-10-17T22:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-rsv 2024-10-17T22:25:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-rsv 2024-10-17T22:25:21+00:00 weekly 0.7 https://trial.medpath.com/news/tryptamine-therapeutics-advances-psilocin-drug-trials-tipranks-com 2024-10-17T22:20:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tryptamine-therapeutics-advances-psilocin-drug-trials-tipranks-com 2024-10-17T22:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-sells-viatris-rights-to-cardio-drug-outside-of-the-u-s-and-europe-biopharma-dive 2024-10-17T21:22:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-sells-viatris-rights-to-cardio-drug-outside-of-the-u-s-and-europe-biopharma-dive 2024-10-17T21:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/dr-nowakowski-on-the-implications-of-the-fda-approval-of-epcoritamab-in-follicular-lymphoma 2024-10-17T20:08:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-nowakowski-on-the-implications-of-the-fda-approval-of-epcoritamab-in-follicular-lymphoma 2024-10-17T20:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/cabozantinib-plus-atezolizumab-fails-to-improve-os-over-subsequent-novel-hormonal 2024-10-17T20:08:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabozantinib-plus-atezolizumab-fails-to-improve-os-over-subsequent-novel-hormonal 2024-10-17T20:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-insights-denileukin-diftitox-in-relapsed-refractory-ctcl-onclive 2024-10-17T20:08:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-insights-denileukin-diftitox-in-relapsed-refractory-ctcl-onclive 2024-10-17T20:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/sage-lays-off-55-of-r-d-workforce-and-refocuses-pipeline-yahoo-finance 2024-10-17T19:58:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-lays-off-55-of-r-d-workforce-and-refocuses-pipeline-yahoo-finance 2024-10-17T19:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/intercept-s-liver-disease-drug-faces-full-approval-delay-following-negative-adcomm 2024-10-17T19:45:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intercept-s-liver-disease-drug-faces-full-approval-delay-following-negative-adcomm 2024-10-17T19:45:48+00:00 weekly 0.7 https://trial.medpath.com/news/the-positive-choices-trial-update-to-study-protocol-for-a-phase-iii-rct-trial-of-a-whole-trials 2024-10-17T19:12:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-positive-choices-trial-update-to-study-protocol-for-a-phase-iii-rct-trial-of-a-whole-trials 2024-10-17T19:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/3-takeaways-from-bcrf-s-webinar-on-metastatic-breast-cancer 2024-10-17T19:06:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-takeaways-from-bcrf-s-webinar-on-metastatic-breast-cancer 2024-10-17T19:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/mcgregor-and-participants-discuss-impact-of-drug-efficacy-and-histology-on-nccrcc-care 2024-10-17T19:02:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mcgregor-and-participants-discuss-impact-of-drug-efficacy-and-histology-on-nccrcc-care 2024-10-17T19:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/conditional-fda-approval-pathway-bill-introduced-in-house-insidehealthpolicy-com 2024-10-17T18:37:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/conditional-fda-approval-pathway-bill-introduced-in-house-insidehealthpolicy-com 2024-10-17T18:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/ab-science-faces-setback-in-ema-approval-for-als-treatment-webdisclosure 2024-10-17T18:35:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ab-science-faces-setback-in-ema-approval-for-als-treatment-webdisclosure 2024-10-17T18:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/buprenorphine-naloxone-vs-methadone-for-the-treatment-of-opioid-use-disorder 2024-10-17T18:29:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buprenorphine-naloxone-vs-methadone-for-the-treatment-of-opioid-use-disorder 2024-10-17T18:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/early-drug-treatment-in-preterm-patients-with-large-patent-ductus-arteriosus-at-28-weeks-or 2024-10-17T18:29:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-drug-treatment-in-preterm-patients-with-large-patent-ductus-arteriosus-at-28-weeks-or 2024-10-17T18:29:18+00:00 weekly 0.7 https://trial.medpath.com/news/more-companies-share-upcoming-aao-presentation-information-modern-retina 2024-10-17T18:15:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/more-companies-share-upcoming-aao-presentation-information-modern-retina 2024-10-17T18:15:20+00:00 weekly 0.7 https://trial.medpath.com/news/speakers-highlight-2024-regulatory-moves-in-hypertension-lipid-diabetes-therapies-healio 2024-10-17T17:51:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/speakers-highlight-2024-regulatory-moves-in-hypertension-lipid-diabetes-therapies-healio 2024-10-17T17:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-study-on-conversion-therapy-of-hepatocellular-carcinoma-bmc-gastroenterology 2024-10-17T17:48:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-study-on-conversion-therapy-of-hepatocellular-carcinoma-bmc-gastroenterology 2024-10-17T17:48:06+00:00 weekly 0.7 https://trial.medpath.com/news/estimating-the-true-prevalence-of-mash-and-masld-in-the-us 2024-10-17T16:36:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/estimating-the-true-prevalence-of-mash-and-masld-in-the-us 2024-10-17T16:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-treating-neurological-diseases-mirage-news 2024-10-17T16:36:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-treating-neurological-diseases-mirage-news 2024-10-17T16:36:44+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-thoracic-radiotherapy-to-first-line-treatment-of-egfr-mutated-metastatic-nsclc 2024-10-17T16:24:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-thoracic-radiotherapy-to-first-line-treatment-of-egfr-mutated-metastatic-nsclc 2024-10-17T16:24:15+00:00 weekly 0.7 https://trial.medpath.com/news/tafasitamab-plus-lenalidomide-wins-approval-in-mexico-for-asct-ineligible-r-r-dlbcl 2024-10-17T16:22:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tafasitamab-plus-lenalidomide-wins-approval-in-mexico-for-asct-ineligible-r-r-dlbcl 2024-10-17T16:22:10+00:00 weekly 0.7 https://trial.medpath.com/news/custom-alterations-mending-genes-for-long-lasting-effects-newswise 2024-10-17T16:17:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/custom-alterations-mending-genes-for-long-lasting-effects-newswise 2024-10-17T16:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/for-fred-hutch-biostatisticians-numbers-are-no-game-fred-hutchinson-cancer-center 2024-10-17T16:04:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/for-fred-hutch-biostatisticians-numbers-are-no-game-fred-hutchinson-cancer-center 2024-10-17T16:04:31+00:00 weekly 0.7 https://trial.medpath.com/news/new-biomarker-predicts-immunotherapy-response-in-hepatocellular-carcinoma 2024-10-17T15:49:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-biomarker-predicts-immunotherapy-response-in-hepatocellular-carcinoma 2024-10-17T15:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/four-people-died-after-receiving-the-russian-sputnik-v-vaccine-telegrafi 2024-10-17T15:37:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/four-people-died-after-receiving-the-russian-sputnik-v-vaccine-telegrafi 2024-10-17T15:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/yourgene-health-cystic-fibrosis-base-assay-receives-ivdr-accreditation 2024-10-17T15:34:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yourgene-health-cystic-fibrosis-base-assay-receives-ivdr-accreditation 2024-10-17T15:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/can-avutometinib-win-the-title-of-first-breakthrough-treatment-for-recurrent-kras-rttnews 2024-10-17T14:33:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-avutometinib-win-the-title-of-first-breakthrough-treatment-for-recurrent-kras-rttnews 2024-10-17T14:33:11+00:00 weekly 0.7 https://trial.medpath.com/news/bioaegis-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-of-gelsolin-an-immune 2024-10-17T14:29:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioaegis-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-of-gelsolin-an-immune 2024-10-17T14:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing 2024-10-17T14:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing 2024-10-17T14:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/biostem-technologies-reports-breakthrough-results-in-a-diabetic-foot-ulcer-wound-biospace 2024-10-17T14:28:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biostem-technologies-reports-breakthrough-results-in-a-diabetic-foot-ulcer-wound-biospace 2024-10-17T14:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/october-17-2024-ggc4h-pilot-finds-spanish-language-intervention-feasible-and 2024-10-17T14:17:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/october-17-2024-ggc4h-pilot-finds-spanish-language-intervention-feasible-and 2024-10-17T14:17:49+00:00 weekly 0.7 https://trial.medpath.com/news/harmonized-data-quality-indicators-maintain-data-quality-in-long-term-clep 2024-10-17T14:00:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harmonized-data-quality-indicators-maintain-data-quality-in-long-term-clep 2024-10-17T14:00:17+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-focused-digital-health-startup-closes-after-an-fda-rejection-stat-news 2024-10-17T13:59:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-focused-digital-health-startup-closes-after-an-fda-rejection-stat-news 2024-10-17T13:59:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-foscarbidopa-foslevodopa-for-motor-fluctuations-in-adults-with-parkinson-disease 2024-10-17T13:53:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-foscarbidopa-foslevodopa-for-motor-fluctuations-in-adults-with-parkinson-disease 2024-10-17T13:53:55+00:00 weekly 0.7 https://trial.medpath.com/news/in-a-breakthrough-indian-scientists-develop-unique-method-to-treat-brain-tuberculosis 2024-10-17T13:53:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-a-breakthrough-indian-scientists-develop-unique-method-to-treat-brain-tuberculosis 2024-10-17T13:53:40+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-t-cell-response-and-safety-of-a-tetravalent-dengue-vaccine-in-healthy-children 2024-10-17T13:48:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-t-cell-response-and-safety-of-a-tetravalent-dengue-vaccine-in-healthy-children 2024-10-17T13:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/avadel-pharmaceuticals-announces-fda-approval-of-lumryztm-sodium-oxybate 2024-10-17T13:46:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avadel-pharmaceuticals-announces-fda-approval-of-lumryztm-sodium-oxybate 2024-10-17T13:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-extends-review-of-obeticholic-acid-ocaliva-snda-for-primary-biliary-cholangitis 2024-10-17T13:41:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-extends-review-of-obeticholic-acid-ocaliva-snda-for-primary-biliary-cholangitis 2024-10-17T13:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/bms-opdivo-bests-pfizer-s-adcetris-in-late-stage-hodgkin-s-lymphoma-study-biospace 2024-10-17T13:19:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bms-opdivo-bests-pfizer-s-adcetris-in-late-stage-hodgkin-s-lymphoma-study-biospace 2024-10-17T13:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/more-evidence-on-glp-1s-and-opioid-addiction-stat-news 2024-10-17T13:09:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/more-evidence-on-glp-1s-and-opioid-addiction-stat-news 2024-10-17T13:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/preparing-for-responsive-management-versus-preparing-for-renal-dialysis-in-multimorbid-trials 2024-10-17T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preparing-for-responsive-management-versus-preparing-for-renal-dialysis-in-multimorbid-trials 2024-10-17T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/alkeus-pharmaceuticals-announces-data-presentations-at-the-american-the-manila-times 2024-10-17T13:01:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-announces-data-presentations-at-the-american-the-manila-times 2024-10-17T13:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-can-approve-cheaper-copycat-of-heart-failure-drug-entresto-judge-says 2024-10-17T12:57:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-can-approve-cheaper-copycat-of-heart-failure-drug-entresto-judge-says 2024-10-17T12:57:50+00:00 weekly 0.7 https://trial.medpath.com/news/csl-vifor-and-travere-therapeutics-announce-swissmedic-approval-of-filspari-quantisnow 2024-10-17T12:47:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/csl-vifor-and-travere-therapeutics-announce-swissmedic-approval-of-filspari-quantisnow 2024-10-17T12:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/zanubrutinib-shows-limited-cost-effectiveness-against-r-bendamustine-for-first-line-cll-treatment-in-china 2024-10-17T12:47:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zanubrutinib-shows-limited-cost-effectiveness-against-r-bendamustine-for-first-line-cll-treatment-in-china 2024-10-17T12:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-announces-rave-lite-to-support-growth-in-early-and-late-stage-clinical-trials 2024-10-17T12:35:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-announces-rave-lite-to-support-growth-in-early-and-late-stage-clinical-trials 2024-10-17T12:35:16+00:00 weekly 0.7 https://trial.medpath.com/news/igc-pharma-announces-patient-enrollment-at-toronto-s-baycrest-in-phase-2-trial 2024-10-17T12:35:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/igc-pharma-announces-patient-enrollment-at-toronto-s-baycrest-in-phase-2-trial 2024-10-17T12:35:02+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-receives-mhra-approval-for-wainzua-in-rare-nerve-disease-attrv-pn 2024-10-17T12:23:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-receives-mhra-approval-for-wainzua-in-rare-nerve-disease-attrv-pn 2024-10-17T12:23:36+00:00 weekly 0.7 https://trial.medpath.com/news/diet-may-improve-brain-health-in-older-adults-with-obesity-national-institute-on-aging 2024-10-17T12:12:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diet-may-improve-brain-health-in-older-adults-with-obesity-national-institute-on-aging 2024-10-17T12:12:22+00:00 weekly 0.7 https://trial.medpath.com/news/more-than-100-women-with-advanced-cancer-have-already-participated-in-the-impact-cnio 2024-10-17T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/more-than-100-women-with-advanced-cancer-have-already-participated-in-the-impact-cnio 2024-10-17T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/teva-and-mabxience-add-additional-oncology-biosimilar-candidate-expanding-strategic 2024-10-17T11:34:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-and-mabxience-add-additional-oncology-biosimilar-candidate-expanding-strategic 2024-10-17T11:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/melanoma-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-10-17T11:31:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/melanoma-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-10-17T11:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/minor-cannabinoid-shows-promise-in-reducing-anxiety-drug-discovery-news 2024-10-17T11:26:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minor-cannabinoid-shows-promise-in-reducing-anxiety-drug-discovery-news 2024-10-17T11:26:20+00:00 weekly 0.7 https://trial.medpath.com/news/marinus-pharmaceuticals-presents-clinical-data-from-pivotal-phase-3-raise-trial-in-morningstar 2024-10-17T11:08:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marinus-pharmaceuticals-presents-clinical-data-from-pivotal-phase-3-raise-trial-in-morningstar 2024-10-17T11:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/rozanolixizumab-efficacious-in-older-patients-with-generalized-myasthenia-gravis-phase 2024-10-17T10:12:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rozanolixizumab-efficacious-in-older-patients-with-generalized-myasthenia-gravis-phase 2024-10-17T10:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/kind-announces-late-breaking-abstract-accepted-for-presentation-on-and017-clinical 2024-10-17T10:10:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kind-announces-late-breaking-abstract-accepted-for-presentation-on-and017-clinical 2024-10-17T10:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/dad-s-use-of-diabetes-med-metformin-won-t-raise-birth-defect-risk 2024-10-17T10:06:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dad-s-use-of-diabetes-med-metformin-won-t-raise-birth-defect-risk 2024-10-17T10:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/concern-over-tga-rejection-of-alzheimer-s-drug-abc-listen 2024-10-17T09:32:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/concern-over-tga-rejection-of-alzheimer-s-drug-abc-listen 2024-10-17T09:32:02+00:00 weekly 0.7 https://trial.medpath.com/news/for-multiple-sclerosis-medication-and-cognitive-behavioral-therapy-can-reduce-fatigue 2024-10-17T09:13:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/for-multiple-sclerosis-medication-and-cognitive-behavioral-therapy-can-reduce-fatigue 2024-10-17T09:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/australia-joins-eu-in-turning-down-alzheimer-s-drug-leqembi-pharmaphorum 2024-10-17T09:00:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/australia-joins-eu-in-turning-down-alzheimer-s-drug-leqembi-pharmaphorum 2024-10-17T09:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/latigo-biotherapeutics-doses-first-participant-in-phase-1-clinical-trial-of-ltg-305-for-non 2024-10-17T08:53:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/latigo-biotherapeutics-doses-first-participant-in-phase-1-clinical-trial-of-ltg-305-for-non 2024-10-17T08:53:15+00:00 weekly 0.7 https://trial.medpath.com/news/7th-annual-oct-dach-conference-to-address-clinical-trial-innovation-investment-and-diversity-challenges 2024-10-17T07:28:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/7th-annual-oct-dach-conference-to-address-clinical-trial-innovation-investment-and-diversity-challenges 2024-10-17T07:28:06+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-analysis-of-single-versus-tandem-autologous-stem-cell-transplantation-in-nature 2024-10-17T06:42:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-analysis-of-single-versus-tandem-autologous-stem-cell-transplantation-in-nature 2024-10-17T06:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-pharmaceuticals-announces-health-canada-approval-of-daybuetm-trofinetide-for 2024-10-17T06:39:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-announces-health-canada-approval-of-daybuetm-trofinetide-for 2024-10-17T06:39:31+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharm-ventures-to-produce-radioantibody-for-atomvie-bioprocess-international 2024-10-17T06:28:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiopharm-ventures-to-produce-radioantibody-for-atomvie-bioprocess-international 2024-10-17T06:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/specialty-drug-coverage-disparities-create-access-barriers-as-pbms-push-for-benefit-integration 2024-10-17T05:43:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/specialty-drug-coverage-disparities-create-access-barriers-as-pbms-push-for-benefit-integration 2024-10-17T05:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-antibiotic-shows-efficacy-safety-in-late-stage-trial-for-uncomplicated-gonorrhea 2024-10-17T05:28:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-antibiotic-shows-efficacy-safety-in-late-stage-trial-for-uncomplicated-gonorrhea 2024-10-17T05:28:39+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-hiv-vaccine-to-induce-virus-specific-neutralizing-antibodies 2024-10-17T05:19:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-human-hiv-vaccine-to-induce-virus-specific-neutralizing-antibodies 2024-10-17T05:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/loncastuximab-tesirine-demonstrates-promise-in-managing-hemophagocytic-pharmacy-times 2024-10-17T04:07:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/loncastuximab-tesirine-demonstrates-promise-in-managing-hemophagocytic-pharmacy-times 2024-10-17T04:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-clinical-trial-testing-digital-mindset-intervention-for-knee-osteoarthritis-pain-and 2024-10-17T02:23:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomized-clinical-trial-testing-digital-mindset-intervention-for-knee-osteoarthritis-pain-and 2024-10-17T02:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/gene-editing-approach-helps-launch-first-in-human-clinical-trial-for-rare-genetic-disease 2024-10-17T01:08:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-editing-approach-helps-launch-first-in-human-clinical-trial-for-rare-genetic-disease 2024-10-17T01:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/ai-support-significantly-improves-her2-scoring-accuracy-in-breast-cancer-diagnosis 2024-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-support-significantly-improves-her2-scoring-accuracy-in-breast-cancer-diagnosis 2024-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glaukos-reports-positive-phase-3-results-for-epioxa-ophthalmology-times 2024-10-16T23:50:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glaukos-reports-positive-phase-3-results-for-epioxa-ophthalmology-times 2024-10-16T23:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/hivma-honors-outstanding-achievements-in-hiv-clinical-education-and-research-with-idsa 2024-10-16T23:04:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hivma-honors-outstanding-achievements-in-hiv-clinical-education-and-research-with-idsa 2024-10-16T23:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-boosts-survival-of-advanced-hodgkin-lymphoma-in-clinical-trial 2024-10-16T21:14:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-boosts-survival-of-advanced-hodgkin-lymphoma-in-clinical-trial 2024-10-16T21:14:53+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-transplants-safe-when-donor-recipient-both-hiv-positive 2024-10-16T21:00:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kidney-transplants-safe-when-donor-recipient-both-hiv-positive 2024-10-16T21:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-expands-its-board-of-directors-with-the-addition-of-drug-stock-titan 2024-10-16T20:58:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-expands-its-board-of-directors-with-the-addition-of-drug-stock-titan 2024-10-16T20:58:10+00:00 weekly 0.7 https://trial.medpath.com/news/acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 2024-10-16T20:18:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 2024-10-16T20:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/study-breast-cancer-drug-shows-potential-for-rare-appendix-cancer 2024-10-16T20:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-breast-cancer-drug-shows-potential-for-rare-appendix-cancer 2024-10-16T20:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-trims-neuroscience-pipeline-seltorexant-in-alzheimer-s-disease-dropped 2024-10-16T19:09:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-trims-neuroscience-pipeline-seltorexant-in-alzheimer-s-disease-dropped 2024-10-16T19:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/atlas-examines-tolerability-of-hedgehog-pathway-inhibitors-and-transition-to-io-in-mbcc 2024-10-16T19:02:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atlas-examines-tolerability-of-hedgehog-pathway-inhibitors-and-transition-to-io-in-mbcc 2024-10-16T19:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/bionj-medidata-tackle-underrepresentation-in-clinical-trials-njbiz 2024-10-16T18:47:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bionj-medidata-tackle-underrepresentation-in-clinical-trials-njbiz 2024-10-16T18:47:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-cleared-medical-devices-lack-proper-vetting-doctors-say-webmd 2024-10-16T18:32:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-cleared-medical-devices-lack-proper-vetting-doctors-say-webmd 2024-10-16T18:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/rna-editing-stocks-soar-on-wave-life-s-breakthrough-trial-data-yahoo-finance 2024-10-16T17:45:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rna-editing-stocks-soar-on-wave-life-s-breakthrough-trial-data-yahoo-finance 2024-10-16T17:45:26+00:00 weekly 0.7 https://trial.medpath.com/news/eximia-research-network-expands-into-iowa-with-acquisition-of-integrated-clinical-trial 2024-10-16T16:47:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eximia-research-network-expands-into-iowa-with-acquisition-of-integrated-clinical-trial 2024-10-16T16:47:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-puts-novavax-flu-vaccine-trials-on-hold-biopharma-dive 2024-10-16T16:20:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-puts-novavax-flu-vaccine-trials-on-hold-biopharma-dive 2024-10-16T16:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-ramucirumab-to-osimertinib-in-tki-naive-egfr-mutant-metastatic-nsclc 2024-10-16T16:04:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-ramucirumab-to-osimertinib-in-tki-naive-egfr-mutant-metastatic-nsclc 2024-10-16T16:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/osimertinib-plus-savolitinib-generates-durable-responses-in-egfr-mutant-met-amplified-nsclc 2024-10-16T15:57:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/osimertinib-plus-savolitinib-generates-durable-responses-in-egfr-mutant-met-amplified-nsclc 2024-10-16T15:57:14+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-and-limmatech-awarded-fda-fast-track-designation-for-tetravalent-shigella 2024-10-16T15:54:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valneva-and-limmatech-awarded-fda-fast-track-designation-for-tetravalent-shigella 2024-10-16T15:54:01+00:00 weekly 0.7 https://trial.medpath.com/news/bridget-koontz-md-on-the-rationale-for-the-phase-2-nrg-gu011-trial-urology-times 2024-10-16T15:43:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridget-koontz-md-on-the-rationale-for-the-phase-2-nrg-gu011-trial-urology-times 2024-10-16T15:43:29+00:00 weekly 0.7 https://trial.medpath.com/news/synedgen-partners-with-barda-for-miist305-development-pharmaceutical-technology 2024-10-16T15:30:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synedgen-partners-with-barda-for-miist305-development-pharmaceutical-technology 2024-10-16T15:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/wave-life-sciences-reveals-rna-editing-breakthrough-reports-first-ever-clinical-proof-of 2024-10-16T15:23:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wave-life-sciences-reveals-rna-editing-breakthrough-reports-first-ever-clinical-proof-of 2024-10-16T15:23:43+00:00 weekly 0.7 https://trial.medpath.com/news/bacterial-vaccine-shows-promise-as-cancer-immunotherapy-eurekalert 2024-10-16T15:16:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bacterial-vaccine-shows-promise-as-cancer-immunotherapy-eurekalert 2024-10-16T15:16:36+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-promising-outlook-with-ntla-2002-s-impressive-phase-ii-results-and 2024-10-16T15:07:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-therapeutics-promising-outlook-with-ntla-2002-s-impressive-phase-ii-results-and 2024-10-16T15:07:44+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-technology-leads-to-life-saving-treatment-for-deadly-skin-reaction 2024-10-16T15:05:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-technology-leads-to-life-saving-treatment-for-deadly-skin-reaction 2024-10-16T15:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/opinion-addition-of-olanzapine-is-effectively-manages-nausea-during-t-dxd-treatment 2024-10-16T15:02:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opinion-addition-of-olanzapine-is-effectively-manages-nausea-during-t-dxd-treatment 2024-10-16T15:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/results-of-phase-i-trial-shed-positive-light-on-uni-494-for-acute-kidney-injury 2024-10-16T14:51:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/results-of-phase-i-trial-shed-positive-light-on-uni-494-for-acute-kidney-injury 2024-10-16T14:51:34+00:00 weekly 0.7 https://trial.medpath.com/news/obsidian-solutions-group-secures-direct-to-phase-ii-award-from-afwerx-to-enhance 2024-10-16T14:48:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obsidian-solutions-group-secures-direct-to-phase-ii-award-from-afwerx-to-enhance 2024-10-16T14:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/us-advisory-committees-pink-sheet-citeline 2024-10-16T14:28:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-advisory-committees-pink-sheet-citeline 2024-10-16T14:28:47+00:00 weekly 0.7 https://trial.medpath.com/news/okyo-pharma-begins-phase-2-trial-for-ncp-treatment-investing-com 2024-10-16T14:25:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/okyo-pharma-begins-phase-2-trial-for-ncp-treatment-investing-com 2024-10-16T14:25:46+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-for-alcon-based-on-potential-fda-approval-of-ar-15512-despite-mixed-phase-3-results 2024-10-16T14:19:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-rating-for-alcon-based-on-potential-fda-approval-of-ar-15512-despite-mixed-phase-3-results 2024-10-16T14:19:06+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-reporting-is-on-the-rise-nature 2024-10-16T14:10:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-reporting-is-on-the-rise-nature 2024-10-16T14:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/adicet-bio-announces-fda-clearance-of-ind-amendment-to-evaluate-adi-001-in-markets-data 2024-10-16T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adicet-bio-announces-fda-clearance-of-ind-amendment-to-evaluate-adi-001-in-markets-data 2024-10-16T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-in-europe-dosed-in-the-clinical-phase-2b-pointer-study-placera 2024-10-16T13:34:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-in-europe-dosed-in-the-clinical-phase-2b-pointer-study-placera 2024-10-16T13:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/a-controversial-approval-for-novocure-s-device-stat-news 2024-10-16T13:18:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-controversial-approval-for-novocure-s-device-stat-news 2024-10-16T13:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/men-and-women-process-pain-differently-study-finds-uc-san-diego-today 2024-10-16T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/men-and-women-process-pain-differently-study-finds-uc-san-diego-today 2024-10-16T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/jaguar-health-launches-fda-approved-oral-mucositis-prescription-product-gelclair-in-the-u-s 2024-10-16T12:34:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jaguar-health-launches-fda-approved-oral-mucositis-prescription-product-gelclair-in-the-u-s 2024-10-16T12:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-expects-new-uk-clinical-trial-regulation-implementation-by-january-2026 2024-10-16T12:32:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-expects-new-uk-clinical-trial-regulation-implementation-by-january-2026 2024-10-16T12:32:19+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-orphan-medicinal-product-designation-for-navenibart-astria 2024-10-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-grants-orphan-medicinal-product-designation-for-navenibart-astria 2024-10-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/theriva-biologics-announces-orphan-medicinal-product-globenewswire 2024-10-16T12:12:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theriva-biologics-announces-orphan-medicinal-product-globenewswire 2024-10-16T12:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/uconn-s-promising-stroke-medicine-one-step-closer-to-clinical-trial-testing 2024-10-16T11:42:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uconn-s-promising-stroke-medicine-one-step-closer-to-clinical-trial-testing 2024-10-16T11:42:06+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-highlights-progress-in-cardiac-myosin-modulation-programs-and-global 2024-10-16T11:36:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-highlights-progress-in-cardiac-myosin-modulation-programs-and-global 2024-10-16T11:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/viiv-healthcare-shows-more-than-99-effectiveness-in-real-world-studies-for-apretude 2024-10-16T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viiv-healthcare-shows-more-than-99-effectiveness-in-real-world-studies-for-apretude 2024-10-16T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-for-emerging-high-intensity-focused 2024-10-16T11:34:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-for-emerging-high-intensity-focused 2024-10-16T11:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/cessatech-announces-that-recruitment-has-today-reached-the-halfway-point-for-patient 2024-10-16T11:19:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cessatech-announces-that-recruitment-has-today-reached-the-halfway-point-for-patient 2024-10-16T11:19:36+00:00 weekly 0.7 https://trial.medpath.com/news/ai-tools-revolutionize-cancer-diagnosis-and-treatment-precision-expert-says 2024-10-16T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-tools-revolutionize-cancer-diagnosis-and-treatment-precision-expert-says 2024-10-16T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shilpa-medicare-s-us-customer-gets-fast-track-approval-for-glioblastoma-drug 2024-10-16T10:58:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shilpa-medicare-s-us-customer-gets-fast-track-approval-for-glioblastoma-drug 2024-10-16T10:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-capvaxivetm-pneumococcal-21-valent-conjugate-vaccine-demonstrates 2024-10-16T10:57:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-capvaxivetm-pneumococcal-21-valent-conjugate-vaccine-demonstrates 2024-10-16T10:57:19+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-published-results-of-analytical-similarity-study-of-biosimilar-candidate-fyb206-and 2024-10-16T10:53:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/formycon-published-results-of-analytical-similarity-study-of-biosimilar-candidate-fyb206-and 2024-10-16T10:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/official-seal-of-approval-for-university-of-central-lancashire-s-clinical-trials-unit 2024-10-16T10:50:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/official-seal-of-approval-for-university-of-central-lancashire-s-clinical-trials-unit 2024-10-16T10:50:27+00:00 weekly 0.7 https://trial.medpath.com/news/what-journalists-should-know-before-diving-into-drug-investigations 2024-10-16T09:49:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-journalists-should-know-before-diving-into-drug-investigations 2024-10-16T09:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/servier-steps-up-commitment-to-digital-innovation-for-patients-with-klineo-partnership 2024-10-16T09:20:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/servier-steps-up-commitment-to-digital-innovation-for-patients-with-klineo-partnership 2024-10-16T09:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/efforts-to-increase-diversity-in-cancer-clinical-trials-fall-short-news-medical 2024-10-16T09:10:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efforts-to-increase-diversity-in-cancer-clinical-trials-fall-short-news-medical 2024-10-16T09:10:38+00:00 weekly 0.7 https://trial.medpath.com/news/who-suspends-approval-process-for-russian-sputnik-v-vaccine-telegrafi 2024-10-16T09:08:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-suspends-approval-process-for-russian-sputnik-v-vaccine-telegrafi 2024-10-16T09:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/uk-launches-2-clinical-trials-into-cannabis-and-childhood-epilepsy-but-serious-concerns 2024-10-16T09:05:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-launches-2-clinical-trials-into-cannabis-and-childhood-epilepsy-but-serious-concerns 2024-10-16T09:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-expert-removing-prior-authorization-for-biomarker-testing-could-improve-cancer-survival-rates 2024-10-16T08:49:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-expert-removing-prior-authorization-for-biomarker-testing-could-improve-cancer-survival-rates 2024-10-16T08:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/canadian-medical-cannabis-outcomes-study-kicks-off-hemp-gazette 2024-10-16T08:44:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/canadian-medical-cannabis-outcomes-study-kicks-off-hemp-gazette 2024-10-16T08:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-gains-4-on-filing-for-dcgi-s-approval-for-its-insulin-injection-news-on-markets 2024-10-16T08:20:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-gains-4-on-filing-for-dcgi-s-approval-for-its-insulin-injection-news-on-markets 2024-10-16T08:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/bioversys-announces-last-patient-last-visit-in-bv100-phase-2-clinical-trial-in-ventilator 2024-10-16T08:14:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioversys-announces-last-patient-last-visit-in-bv100-phase-2-clinical-trial-in-ventilator 2024-10-16T08:14:11+00:00 weekly 0.7 https://trial.medpath.com/news/bostongene-and-sarah-cannon-research-institute-collaborate-to-accelerate-the-biospace 2024-10-16T07:37:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bostongene-and-sarah-cannon-research-institute-collaborate-to-accelerate-the-biospace 2024-10-16T07:37:01+00:00 weekly 0.7 https://trial.medpath.com/news/avs-enrolls-first-patient-in-u-s-pivotal-intravascular-lithotripsy-study-biospace 2024-10-16T07:14:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avs-enrolls-first-patient-in-u-s-pivotal-intravascular-lithotripsy-study-biospace 2024-10-16T07:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/how-genes-determine-the-effectiveness-of-diets-in-irritable-bowel-syndrome 2024-10-16T07:13:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-genes-determine-the-effectiveness-of-diets-in-irritable-bowel-syndrome 2024-10-16T07:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/language-barriers-in-clinical-research-trial-term-deters-patient-participation-study-finds 2024-10-16T06:51:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/language-barriers-in-clinical-research-trial-term-deters-patient-participation-study-finds 2024-10-16T06:51:23+00:00 weekly 0.7 https://trial.medpath.com/news/gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary 2024-10-16T06:05:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary 2024-10-16T06:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/focus-on-long-term-protection-european-biotechnology-magazine 2024-10-16T06:01:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/focus-on-long-term-protection-european-biotechnology-magazine 2024-10-16T06:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/rising-costs-and-coverage-challenges-shape-anti-obesity-medication-landscape-in-us 2024-10-16T05:30:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rising-costs-and-coverage-challenges-shape-anti-obesity-medication-landscape-in-us 2024-10-16T05:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-announces-that-tagrisso-r-plus-orpathys-r-demonstrated-high-clinically 2024-10-16T05:26:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-announces-that-tagrisso-r-plus-orpathys-r-demonstrated-high-clinically 2024-10-16T05:26:28+00:00 weekly 0.7 https://trial.medpath.com/news/stampede2-trial-explores-combination-niraparib-and-abiraterone-in-mhspc-urotoday 2024-10-16T05:05:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stampede2-trial-explores-combination-niraparib-and-abiraterone-in-mhspc-urotoday 2024-10-16T05:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-affirmed-for-novocure-as-fda-approval-expands-optune-s-market-potential 2024-10-16T04:43:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-rating-affirmed-for-novocure-as-fda-approval-expands-optune-s-market-potential 2024-10-16T04:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/oncodesign-precision-medicine-s-a-inside-information-other-news-releases 2024-10-16T03:34:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncodesign-precision-medicine-s-a-inside-information-other-news-releases 2024-10-16T03:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-files-patent-lawsuit-against-moderna-over-mrna-vaccine-technology 2024-10-16T02:59:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-files-patent-lawsuit-against-moderna-over-mrna-vaccine-technology 2024-10-16T02:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharm-advances-6-new-drugs-into-clinical-trials-for-hypertension-diabetes-and-cancer-kbr 2024-10-16T02:43:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanmi-pharm-advances-6-new-drugs-into-clinical-trials-for-hypertension-diabetes-and-cancer-kbr 2024-10-16T02:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/annexon-to-present-new-phase-2-archer-data-for-anx007-in-dry-amd-patients-with-less 2024-10-16T02:23:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annexon-to-present-new-phase-2-archer-data-for-anx007-in-dry-amd-patients-with-less 2024-10-16T02:23:44+00:00 weekly 0.7 https://trial.medpath.com/news/nyrada-gears-up-for-phase-i-clinical-trials-sharecafe 2024-10-16T00:45:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nyrada-gears-up-for-phase-i-clinical-trials-sharecafe 2024-10-16T00:45:21+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-forms-scientific-and-patient-advisory-board-biospace 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-forms-scientific-and-patient-advisory-board-biospace 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-efficacy-of-the-blood-stage-malaria-vaccine-rh5 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-and-efficacy-of-the-blood-stage-malaria-vaccine-rh5 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xyra-announces-fda-label-guidance-for-managing-atrial-fibrillation-with-budiodarone-and-wearable-monitoring-devices 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xyra-announces-fda-label-guidance-for-managing-atrial-fibrillation-with-budiodarone-and-wearable-monitoring-devices 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-sallman-on-the-significance-of-the-fda-approval-of-luspatercept-for-lower-risk-mds 2024-10-15T22:32:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-sallman-on-the-significance-of-the-fda-approval-of-luspatercept-for-lower-risk-mds 2024-10-15T22:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102 2024-10-15T22:10:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102 2024-10-15T22:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/catalyst-orthoscience-announces-fda-510-k-clearance-for-shoulder-fracture-system-and 2024-10-15T21:56:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/catalyst-orthoscience-announces-fda-510-k-clearance-for-shoulder-fracture-system-and 2024-10-15T21:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/imforte-shows-benefits-of-lurbinectedin-atezolizumab-in-es-sclc-targeted-oncology 2024-10-15T21:30:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imforte-shows-benefits-of-lurbinectedin-atezolizumab-in-es-sclc-targeted-oncology 2024-10-15T21:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-optune-lua-for-metastatic-nsclc-after-platinum-based-chemotherapy 2024-10-15T21:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-optune-lua-for-metastatic-nsclc-after-platinum-based-chemotherapy 2024-10-15T21:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/meiragtx-looks-to-a-phase-iii-in-parkinson-s-bioworld 2024-10-15T21:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meiragtx-looks-to-a-phase-iii-in-parkinson-s-bioworld 2024-10-15T21:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/capmatinib-in-met-exon-14-mutated-nsclc-the-asco-post 2024-10-15T20:59:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/capmatinib-in-met-exon-14-mutated-nsclc-the-asco-post 2024-10-15T20:59:19+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102-stock-titan 2024-10-15T20:41:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102-stock-titan 2024-10-15T20:41:21+00:00 weekly 0.7 https://trial.medpath.com/news/uropot-study-protocol-for-a-randomized-double-blind-phase-i-ii-trial-for-metabolism-based 2024-10-15T20:34:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uropot-study-protocol-for-a-randomized-double-blind-phase-i-ii-trial-for-metabolism-based 2024-10-15T20:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-s-cold-calling-cgt-space-at-a-critical-crossroads-pharmaceutical-executive 2024-10-15T20:08:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-s-cold-calling-cgt-space-at-a-critical-crossroads-pharmaceutical-executive 2024-10-15T20:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/eu-accelerated-assessment-tracker-insights-citeline 2024-10-15T19:41:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-accelerated-assessment-tracker-insights-citeline 2024-10-15T19:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and 2024-10-15T19:27:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gan-lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and 2024-10-15T19:27:03+00:00 weekly 0.7 https://trial.medpath.com/news/study-resistance-to-antibody-rare-in-rsv-breakthrough-cases-cidrap 2024-10-15T19:19:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-resistance-to-antibody-rare-in-rsv-breakthrough-cases-cidrap 2024-10-15T19:19:36+00:00 weekly 0.7 https://trial.medpath.com/news/ultomiris-over-half-year-helped-most-gmg-patients-in-phase-3-trial 2024-10-15T19:05:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultomiris-over-half-year-helped-most-gmg-patients-in-phase-3-trial 2024-10-15T19:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-heparin-link-two-phases-of-alzheimer-s-damage-prion-disease-testing 2024-10-15T18:30:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-heparin-link-two-phases-of-alzheimer-s-damage-prion-disease-testing 2024-10-15T18:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-drug-rk-33-shows-promise-in-treating-breast-cancer-bone-metastasis 2024-10-15T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experimental-drug-rk-33-shows-promise-in-treating-breast-cancer-bone-metastasis 2024-10-15T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/immune-profiles-forecast-immunotherapy-side-effects-drug-discovery-and-development 2024-10-15T17:49:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immune-profiles-forecast-immunotherapy-side-effects-drug-discovery-and-development 2024-10-15T17:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/18f-rhpsma-7-3-pet-mri-demonstrates-high-detection-in-recurrent-prostate-cancer-urology-times 2024-10-15T17:38:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/18f-rhpsma-7-3-pet-mri-demonstrates-high-detection-in-recurrent-prostate-cancer-urology-times 2024-10-15T17:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/why-are-we-still-seeing-gaps-in-women-s-heart-care 2024-10-15T17:23:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-are-we-still-seeing-gaps-in-women-s-heart-care 2024-10-15T17:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/lyka-s-patent-pending-drug-pregabalin-gel-8-w-w-receives-approval-from-cdsco 2024-10-15T17:17:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyka-s-patent-pending-drug-pregabalin-gel-8-w-w-receives-approval-from-cdsco 2024-10-15T17:17:05+00:00 weekly 0.7 https://trial.medpath.com/news/eye-on-pharma-aflibercept-legal-drama-pbm-humira-biosimilars-denosumab-regulatory-review 2024-10-15T17:10:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eye-on-pharma-aflibercept-legal-drama-pbm-humira-biosimilars-denosumab-regulatory-review 2024-10-15T17:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/allyx-therapeutics-awarded-3-3-million-nih-grant-to-globenewswire 2024-10-15T17:06:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allyx-therapeutics-awarded-3-3-million-nih-grant-to-globenewswire 2024-10-15T17:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-gets-fda-approval-for-meningococcal-vaccine-manila-standard 2024-10-15T16:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-gets-fda-approval-for-meningococcal-vaccine-manila-standard 2024-10-15T16:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/lyra-therapeutics-fully-enrolls-pivotal-phase-3-enlighten-2-globenewswire 2024-10-15T15:54:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyra-therapeutics-fully-enrolls-pivotal-phase-3-enlighten-2-globenewswire 2024-10-15T15:54:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-long-term-laser-treatment-for-inflammatory-acne-vulgaris-hcplive 2024-10-15T15:51:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-long-term-laser-treatment-for-inflammatory-acne-vulgaris-hcplive 2024-10-15T15:51:19+00:00 weekly 0.7 https://trial.medpath.com/news/intermountain-medical-center-first-in-nation-to-use-fda-approved-device-to-treat-life 2024-10-15T15:49:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intermountain-medical-center-first-in-nation-to-use-fda-approved-device-to-treat-life 2024-10-15T15:49:44+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-a-mobile-health-intervention-based-on-a-multitheoretical-model-of-health-behavior 2024-10-15T15:38:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effects-of-a-mobile-health-intervention-based-on-a-multitheoretical-model-of-health-behavior 2024-10-15T15:38:53+00:00 weekly 0.7 https://trial.medpath.com/news/healix-study-aims-to-reduce-cervical-cancer-rates-and-health-disparities-uc-davis-health 2024-10-15T15:29:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healix-study-aims-to-reduce-cervical-cancer-rates-and-health-disparities-uc-davis-health 2024-10-15T15:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/shining-new-light-on-breast-cancer-cells-mass-general-giving 2024-10-15T15:25:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shining-new-light-on-breast-cancer-cells-mass-general-giving 2024-10-15T15:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-invests-in-molecular-glue-jazz-meiragtx-shares-rise-on-drug-data-biopharma-dive 2024-10-15T15:14:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-invests-in-molecular-glue-jazz-meiragtx-shares-rise-on-drug-data-biopharma-dive 2024-10-15T15:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/msk-research-highlights-october-15-2024-memorial-sloan-kettering-cancer-center 2024-10-15T15:11:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/msk-research-highlights-october-15-2024-memorial-sloan-kettering-cancer-center 2024-10-15T15:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/uk-plans-weight-loss-drug-trials-to-get-people-back-to-work-dw 2024-10-15T15:07:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-plans-weight-loss-drug-trials-to-get-people-back-to-work-dw 2024-10-15T15:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-market-size-to-worth-usd-85-37-billion-by-2033-straits-research 2024-10-15T15:02:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-market-size-to-worth-usd-85-37-billion-by-2033-straits-research 2024-10-15T15:02:10+00:00 weekly 0.7 https://trial.medpath.com/news/ventyx-biosciences-presents-new-52-week-results-from-the-phase-2-trial-of-vtx002 2024-10-15T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ventyx-biosciences-presents-new-52-week-results-from-the-phase-2-trial-of-vtx002 2024-10-15T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/pharmamar-announces-positive-and-statistically-significant-overall-survival-and-markets-data 2024-10-15T14:36:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmamar-announces-positive-and-statistically-significant-overall-survival-and-markets-data 2024-10-15T14:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-open-label-dose-escalation-trial-with-expansion-cohorts-to-evaluate-the 2024-10-15T14:35:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-human-open-label-dose-escalation-trial-with-expansion-cohorts-to-evaluate-the 2024-10-15T14:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/predicting-response-to-rtms-in-mdd-psychiatric-times 2024-10-15T14:33:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/predicting-response-to-rtms-in-mdd-psychiatric-times 2024-10-15T14:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/keynote-811-pembrolizumab-combination-in-first-line-setting-improves-overall-survival 2024-10-15T14:22:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keynote-811-pembrolizumab-combination-in-first-line-setting-improves-overall-survival 2024-10-15T14:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/laura-j-van-t-veer-phd-honored-with-2024-william-l-mcguire-memorial-lecture-award 2024-10-15T14:18:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/laura-j-van-t-veer-phd-honored-with-2024-william-l-mcguire-memorial-lecture-award 2024-10-15T14:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/chiglitazar-for-the-treatment-of-mash-phase-ii-clinical-study-selected-for-oral-presentation 2024-10-15T14:17:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chiglitazar-for-the-treatment-of-mash-phase-ii-clinical-study-selected-for-oral-presentation 2024-10-15T14:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/alzamend-neuro-regains-compliance-with-nasdaq-listing-standards-alzn-stock-news 2024-10-15T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzamend-neuro-regains-compliance-with-nasdaq-listing-standards-alzn-stock-news 2024-10-15T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/trop2-offers-attractive-therapeutic-target-in-breast-cancer-and-other-solid-tumors-onclive 2024-10-15T14:07:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trop2-offers-attractive-therapeutic-target-in-breast-cancer-and-other-solid-tumors-onclive 2024-10-15T14:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/remote-monitoring-of-rheumatoid-arthritis-remora-study-protocol-for-a-stepped-wedge-trials 2024-10-15T13:47:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remote-monitoring-of-rheumatoid-arthritis-remora-study-protocol-for-a-stepped-wedge-trials 2024-10-15T13:47:56+00:00 weekly 0.7 https://trial.medpath.com/news/government-to-spend-ps300m-on-weight-loss-drug-trials-the-times 2024-10-15T13:41:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/government-to-spend-ps300m-on-weight-loss-drug-trials-the-times 2024-10-15T13:41:04+00:00 weekly 0.7 https://trial.medpath.com/news/ocular-therapeutixtm-announces-accelerated-timelines-for-sol-1-registrational-trial-biospace 2024-10-15T13:40:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocular-therapeutixtm-announces-accelerated-timelines-for-sol-1-registrational-trial-biospace 2024-10-15T13:40:25+00:00 weekly 0.7 https://trial.medpath.com/news/genprex-receives-safety-review-committee-approval-to-advance-to-highest-dose-group-in 2024-10-15T13:38:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genprex-receives-safety-review-committee-approval-to-advance-to-highest-dose-group-in 2024-10-15T13:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-omvoh-beats-j-j-s-stelara-in-head-to-head-phase-iii-crohn-s-disease-trial 2024-10-15T13:33:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-s-omvoh-beats-j-j-s-stelara-in-head-to-head-phase-iii-crohn-s-disease-trial 2024-10-15T13:33:41+00:00 weekly 0.7 https://trial.medpath.com/news/immune-based-subgroups-uncover-diverse-tumor-immunogenicity-and-implications-for-frontiers 2024-10-15T13:21:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immune-based-subgroups-uncover-diverse-tumor-immunogenicity-and-implications-for-frontiers 2024-10-15T13:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/october-15-2024-case-study-describes-a-reassessment-of-sample-size-in-an-ongoing 2024-10-15T13:17:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/october-15-2024-case-study-describes-a-reassessment-of-sample-size-in-an-ongoing 2024-10-15T13:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/lantern-pharma-s-investigational-drug-candidate-lp-184-receives-fast-track-yahoo-finance 2024-10-15T13:11:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantern-pharma-s-investigational-drug-candidate-lp-184-receives-fast-track-yahoo-finance 2024-10-15T13:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-dosing-of-first-patient-in-phase-i-ii-clinical-trial-of-amt-162-for-the 2024-10-15T13:05:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-announces-dosing-of-first-patient-in-phase-i-ii-clinical-trial-of-amt-162-for-the 2024-10-15T13:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/how-will-manchester-weight-loss-drug-trial-for-unemployed-work-bbc 2024-10-15T13:03:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-will-manchester-weight-loss-drug-trial-for-unemployed-work-bbc 2024-10-15T13:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-research-launches-decentralized-clinical-trial-in-parkinson-s-disease 2024-10-15T12:37:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptive-research-launches-decentralized-clinical-trial-in-parkinson-s-disease 2024-10-15T12:37:43+00:00 weekly 0.7 https://trial.medpath.com/news/immuneering-granted-orphan-drug-designation-for-imm-1-104-globenewswire 2024-10-15T12:35:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuneering-granted-orphan-drug-designation-for-imm-1-104-globenewswire 2024-10-15T12:35:01+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-poster-presentation-of-novel-thio-prodrugs-at-ena-2024 2024-10-15T12:23:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-poster-presentation-of-novel-thio-prodrugs-at-ena-2024 2024-10-15T12:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-clinical-advances-across-hepatitis-delta-and-hepatitis-b 2024-10-15T12:19:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-announces-clinical-advances-across-hepatitis-delta-and-hepatitis-b 2024-10-15T12:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimer-s-studies-paving-the-way-to-ndas 2024-10-15T12:19:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimer-s-studies-paving-the-way-to-ndas 2024-10-15T12:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-provides-phase-3-clinical-engagement-update-in-metastatic-breast-cancer-pivotal-study 2024-10-15T12:07:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/briacell-provides-phase-3-clinical-engagement-update-in-metastatic-breast-cancer-pivotal-study 2024-10-15T12:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-anlotinib-hydrochloride-in-advanced-gastric-adenocarcinoma-and-nature 2024-10-15T12:06:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-plus-anlotinib-hydrochloride-in-advanced-gastric-adenocarcinoma-and-nature 2024-10-15T12:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/contego-medical-s-neuroguard-iep-system-receives-fda-approval-for-carotid-prweb 2024-10-15T12:02:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/contego-medical-s-neuroguard-iep-system-receives-fda-approval-for-carotid-prweb 2024-10-15T12:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/hoth-therapeutics-awarded-key-us-patent-for-groundbreaking-alzheimer-s-treatment-and 2024-10-15T11:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hoth-therapeutics-awarded-key-us-patent-for-groundbreaking-alzheimer-s-treatment-and 2024-10-15T11:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/airway-therapeutics-to-launch-a-multinational-phase-3-trial-of-zelpultide-alfa-for-preterm 2024-10-15T11:01:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/airway-therapeutics-to-launch-a-multinational-phase-3-trial-of-zelpultide-alfa-for-preterm 2024-10-15T11:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/pheast-partners-with-lonza-to-produce-cancer-gobbling-cd24-drug-bioprocess-international 2024-10-15T10:50:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pheast-partners-with-lonza-to-produce-cancer-gobbling-cd24-drug-bioprocess-international 2024-10-15T10:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-clearance-for-spectralis-flex-module-expanding-access-to-advanced-biospace 2024-10-15T10:49:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-clearance-for-spectralis-flex-module-expanding-access-to-advanced-biospace 2024-10-15T10:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/wearable-tech-study-delivers-strong-results-for-cmt-clinical-trials-ein-presswire 2024-10-15T10:23:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wearable-tech-study-delivers-strong-results-for-cmt-clinical-trials-ein-presswire 2024-10-15T10:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/zeo-scientifix-a-leading-south-florida-biotechnology-company-launches-regenerative 2024-10-15T10:17:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zeo-scientifix-a-leading-south-florida-biotechnology-company-launches-regenerative 2024-10-15T10:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/ananda-scientific-announces-a-clinical-trial-evaluating-nantheiatm-atl5-in-the-treatment 2024-10-15T10:15:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ananda-scientific-announces-a-clinical-trial-evaluating-nantheiatm-atl5-in-the-treatment 2024-10-15T10:15:23+00:00 weekly 0.7 https://trial.medpath.com/news/ema-drafts-concept-paper-for-future-radiopharmaceuticals-guideline-raps 2024-10-15T10:05:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-drafts-concept-paper-for-future-radiopharmaceuticals-guideline-raps 2024-10-15T10:05:54+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-applies-for-eu-approval-for-drug-to-treat-menopausal-symptoms-marketscreener 2024-10-15T09:38:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-applies-for-eu-approval-for-drug-to-treat-menopausal-symptoms-marketscreener 2024-10-15T09:38:55+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-diamond-phase-3-program-in-diabetic-macular-edema-globenewswire 2024-10-15T08:05:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oculis-diamond-phase-3-program-in-diabetic-macular-edema-globenewswire 2024-10-15T08:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/adolescent-drug-overdose-deaths-show-first-decline-since-pandemic-onset 2024-10-15T07:13:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adolescent-drug-overdose-deaths-show-first-decline-since-pandemic-onset 2024-10-15T07:13:39+00:00 weekly 0.7 https://trial.medpath.com/news/dr-voss-on-the-clinical-significance-of-the-keynote-564-study-in-ccrcc-onclive 2024-10-15T07:07:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-voss-on-the-clinical-significance-of-the-keynote-564-study-in-ccrcc-onclive 2024-10-15T07:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/italy-italian-medicine-agency-new-guidelines-on-clinical-trials-global-compliance-news 2024-10-15T06:52:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/italy-italian-medicine-agency-new-guidelines-on-clinical-trials-global-compliance-news 2024-10-15T06:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/stratosphere-2-study-protocol-for-a-response-adaptive-randomised-placebo-controlled-trials 2024-10-15T06:28:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stratosphere-2-study-protocol-for-a-response-adaptive-randomised-placebo-controlled-trials 2024-10-15T06:28:54+00:00 weekly 0.7 https://trial.medpath.com/news/penumbra-inc-announces-completion-of-thunder-ide-study-enrollment-for-acute-ischemic-stroke 2024-10-15T06:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/penumbra-inc-announces-completion-of-thunder-ide-study-enrollment-for-acute-ischemic-stroke 2024-10-15T06:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-completes-recruitment-of-its-ares-phase-3-trial-for-maat013-to-treat-acute 2024-10-15T05:36:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maat-pharma-completes-recruitment-of-its-ares-phase-3-trial-for-maat013-to-treat-acute 2024-10-15T05:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/experts-discuss-treatment-strategies-for-advanced-rcc-focus-on-nivolumab-ipilimumab-combination 2024-10-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-discuss-treatment-strategies-for-advanced-rcc-focus-on-nivolumab-ipilimumab-combination 2024-10-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chest-2024-major-breakthroughs-in-copd-treatment-and-pulmonary-embolism-management-unveiled 2024-10-15T04:55:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chest-2024-major-breakthroughs-in-copd-treatment-and-pulmonary-embolism-management-unveiled 2024-10-15T04:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/forbion-secures-eur2-billion-in-landmark-biotech-investment-funds 2024-10-15T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/forbion-secures-eur2-billion-in-landmark-biotech-investment-funds 2024-10-15T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-tremfya-and-carvykti-show-strong-growth-as-company-braces-for-stelara-biosimilar-competition 2024-10-15T04:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-tremfya-and-carvykti-show-strong-growth-as-company-braces-for-stelara-biosimilar-competition 2024-10-15T04:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grapples-with-ai-ml-medical-device-oversight-regulatory-gaps-and-bias-concerns-emerge 2024-10-15T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grapples-with-ai-ml-medical-device-oversight-regulatory-gaps-and-bias-concerns-emerge 2024-10-15T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drugs-and-clinical-trials-amendment-rules-2024-mondaq 2024-10-15T02:12:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drugs-and-clinical-trials-amendment-rules-2024-mondaq 2024-10-15T02:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/pharmabcine-announces-safety-approval-for-4mg-single-dose-cohort-in-phase-1-clinical 2024-10-15T02:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmabcine-announces-safety-approval-for-4mg-single-dose-cohort-in-phase-1-clinical 2024-10-15T02:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/paratek-pharmaceuticals-announces-presentation-of-several-new-studies-of-nuzyra-biospace 2024-10-15T01:01:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paratek-pharmaceuticals-announces-presentation-of-several-new-studies-of-nuzyra-biospace 2024-10-15T01:01:45+00:00 weekly 0.7 https://trial.medpath.com/news/plasma-proteomic-and-polygenic-profiling-improve-risk-stratification-and-personalized 2024-10-15T00:16:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plasma-proteomic-and-polygenic-profiling-improve-risk-stratification-and-personalized 2024-10-15T00:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/tenecteplase-plus-thrombectomy-improves-stroke-outcomes-in-chinese-trial 2024-10-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tenecteplase-plus-thrombectomy-improves-stroke-outcomes-in-chinese-trial 2024-10-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/taysha-seeks-to-overturn-natural-history-trends-with-rett-syndrome-gene-therapy-in-dual 2024-10-14T22:34:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/taysha-seeks-to-overturn-natural-history-trends-with-rett-syndrome-gene-therapy-in-dual 2024-10-14T22:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/kod-kodiak-sciences-inc-latest-stock-news-market-updates 2024-10-14T21:56:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kod-kodiak-sciences-inc-latest-stock-news-market-updates 2024-10-14T21:56:43+00:00 weekly 0.7 https://trial.medpath.com/news/dr-boreham-s-crucible-can-this-small-aussie-company-meet-mnd-s-sizeable-need 2024-10-14T19:39:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-boreham-s-crucible-can-this-small-aussie-company-meet-mnd-s-sizeable-need 2024-10-14T19:39:58+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-established-pharmaceutical-companies-in-bringing-cell-therapy-to-cgtlive-r 2024-10-14T19:34:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-role-of-established-pharmaceutical-companies-in-bringing-cell-therapy-to-cgtlive-r 2024-10-14T19:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/selinexor-paves-the-way-for-more-affordable-effective-treatment-options-in-myelofibrosis 2024-10-14T19:07:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/selinexor-paves-the-way-for-more-affordable-effective-treatment-options-in-myelofibrosis 2024-10-14T19:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/sotagliflozin-in-patients-with-type-1-diabetes-and-ckd-to-be-discussed-at-october-fda 2024-10-14T18:49:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sotagliflozin-in-patients-with-type-1-diabetes-and-ckd-to-be-discussed-at-october-fda 2024-10-14T18:49:08+00:00 weekly 0.7 https://trial.medpath.com/news/electroconvulsive-therapy-for-the-treatment-of-dementia-symptoms-psychiatric-times 2024-10-14T18:27:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/electroconvulsive-therapy-for-the-treatment-of-dementia-symptoms-psychiatric-times 2024-10-14T18:27:50+00:00 weekly 0.7 https://trial.medpath.com/news/dr-john-byrd-87-and-dr-tom-goodwin-credited-with-early-work-on-cancer-drug-recently 2024-10-14T18:05:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-john-byrd-87-and-dr-tom-goodwin-credited-with-early-work-on-cancer-drug-recently 2024-10-14T18:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ceftobiprole-medocaril-sodium-for-3-indications-drug-topics 2024-10-14T17:43:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ceftobiprole-medocaril-sodium-for-3-indications-drug-topics 2024-10-14T17:43:34+00:00 weekly 0.7 https://trial.medpath.com/news/the-u-s-fda-grants-fast-track-designation-to-coherent-biopharma-s-cbp-1008 2024-10-14T17:18:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-u-s-fda-grants-fast-track-designation-to-coherent-biopharma-s-cbp-1008 2024-10-14T17:18:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-facing-pressure-to-review-position-on-zepbound-mounjaro-shortage-biopharma-dive 2024-10-14T17:17:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-facing-pressure-to-review-position-on-zepbound-mounjaro-shortage-biopharma-dive 2024-10-14T17:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-teams-with-the-big-ten-conference-to-raise-blood-pharmaceutical-executive 2024-10-14T17:17:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-teams-with-the-big-ten-conference-to-raise-blood-pharmaceutical-executive 2024-10-14T17:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/recon-fda-may-rethink-shortage-listing-for-eli-lilly-s-tirzepatide-raps 2024-10-14T16:40:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-fda-may-rethink-shortage-listing-for-eli-lilly-s-tirzepatide-raps 2024-10-14T16:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-therapy-may-reduce-suicidal-ideation-risk-for-adolescents-with-obesity-healio 2024-10-14T15:54:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-therapy-may-reduce-suicidal-ideation-risk-for-adolescents-with-obesity-healio 2024-10-14T15:54:35+00:00 weekly 0.7 https://trial.medpath.com/news/collaboration-to-support-clinical-development-of-psma-targeting-theranostics-in-japan 2024-10-14T15:50:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/collaboration-to-support-clinical-development-of-psma-targeting-theranostics-in-japan 2024-10-14T15:50:13+00:00 weekly 0.7 https://trial.medpath.com/news/anti-obesity-drugs-tied-to-lower-risk-of-suicidal-thoughts-or-attempts-among-young-people 2024-10-14T15:24:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anti-obesity-drugs-tied-to-lower-risk-of-suicidal-thoughts-or-attempts-among-young-people 2024-10-14T15:24:17+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-and-zydus-lifesciences-initiate-second-phase-proof-of-concept-trial-for-desidustat-in 2024-10-14T15:14:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icmr-and-zydus-lifesciences-initiate-second-phase-proof-of-concept-trial-for-desidustat-in 2024-10-14T15:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/cf-may-have-stifled-her-before-but-now-she-can-laugh-sanford-health-news 2024-10-14T15:04:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cf-may-have-stifled-her-before-but-now-she-can-laugh-sanford-health-news 2024-10-14T15:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/the-october-2024-research-roundup-first10em 2024-10-14T14:52:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-october-2024-research-roundup-first10em 2024-10-14T14:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/new-directions-in-all-cml-and-cll-treatment-the-asco-post 2024-10-14T14:52:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-directions-in-all-cml-and-cll-treatment-the-asco-post 2024-10-14T14:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/tpst-stock-touches-52-week-low-at-0-92-amid-market-challenges-investing-com 2024-10-14T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tpst-stock-touches-52-week-low-at-0-92-amid-market-challenges-investing-com 2024-10-14T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/fianlimab-combo-shows-activity-in-advanced-melanoma-subtypes-cancer-network 2024-10-14T14:45:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fianlimab-combo-shows-activity-in-advanced-melanoma-subtypes-cancer-network 2024-10-14T14:45:45+00:00 weekly 0.7 https://trial.medpath.com/news/aiims-bathinda-makes-breakthrough-in-stem-cell-therapy-research-for-heart-ailments 2024-10-14T14:35:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aiims-bathinda-makes-breakthrough-in-stem-cell-therapy-research-for-heart-ailments 2024-10-14T14:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/biofrontera-inc-announces-database-lock-of-phase-3-study-of-ameluz-globenewswire 2024-10-14T14:31:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biofrontera-inc-announces-database-lock-of-phase-3-study-of-ameluz-globenewswire 2024-10-14T14:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/mixed-active-metabolites-of-the-snp-6-series-of-novel-compounds-mitigate-metabolic 2024-10-14T14:29:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mixed-active-metabolites-of-the-snp-6-series-of-novel-compounds-mitigate-metabolic 2024-10-14T14:29:34+00:00 weekly 0.7 https://trial.medpath.com/news/ischemic-stroke-drug-pipeline-research-report-2024-yahoo-finance 2024-10-14T14:27:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ischemic-stroke-drug-pipeline-research-report-2024-yahoo-finance 2024-10-14T14:27:12+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-preps-for-q3-earnings-as-medtech-expands-but-stock-sends-mixed-signals 2024-10-14T14:19:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-preps-for-q3-earnings-as-medtech-expands-but-stock-sends-mixed-signals 2024-10-14T14:19:48+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-s-stock-falls-as-analyst-warns-that-hype-around-obesity-drug-is-baked-in-morningstar 2024-10-14T14:18:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-s-stock-falls-as-analyst-warns-that-hype-around-obesity-drug-is-baked-in-morningstar 2024-10-14T14:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/dr-tao-on-the-efficacy-of-avelumab-cetuximab-radiotherapy-in-cisplain-eligibile-vs 2024-10-14T14:16:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-tao-on-the-efficacy-of-avelumab-cetuximab-radiotherapy-in-cisplain-eligibile-vs 2024-10-14T14:16:15+00:00 weekly 0.7 https://trial.medpath.com/news/chemoimmunotherapy-is-at-the-forefront-of-the-perioperative-nsclc-paradigm-onclive 2024-10-14T14:08:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemoimmunotherapy-is-at-the-forefront-of-the-perioperative-nsclc-paradigm-onclive 2024-10-14T14:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-to-acquire-longboard-pharmaceuticals-in-a-strategic-deal-significantly-enhancing 2024-10-14T13:55:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lundbeck-to-acquire-longboard-pharmaceuticals-in-a-strategic-deal-significantly-enhancing 2024-10-14T13:55:45+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-doses-first-subject-in-phase-i-solid-tumour-trial 2024-10-14T13:43:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-doses-first-subject-in-phase-i-solid-tumour-trial 2024-10-14T13:43:45+00:00 weekly 0.7 https://trial.medpath.com/news/lifevantage-introduces-the-mindbody-glp-1-systemtm-transforming-weight-management 2024-10-14T13:22:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lifevantage-introduces-the-mindbody-glp-1-systemtm-transforming-weight-management 2024-10-14T13:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-lomecel-btm-data-in-alzheimer-s-disease-selected-for-late-breaking-poster 2024-10-14T13:21:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longeveron-r-lomecel-btm-data-in-alzheimer-s-disease-selected-for-late-breaking-poster 2024-10-14T13:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/vivance-completes-pre-pivotal-trial-of-wearable-dialysis-device-kilgore-news-herald 2024-10-14T13:20:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivance-completes-pre-pivotal-trial-of-wearable-dialysis-device-kilgore-news-herald 2024-10-14T13:20:19+00:00 weekly 0.7 https://trial.medpath.com/news/exelixis-and-merck-collaborate-on-cancer-drug-trials-investing-com 2024-10-14T13:20:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exelixis-and-merck-collaborate-on-cancer-drug-trials-investing-com 2024-10-14T13:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-stock-holds-price-target-on-fda-approval-investing-com-uk 2024-10-14T13:17:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relay-therapeutics-stock-holds-price-target-on-fda-approval-investing-com-uk 2024-10-14T13:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/early-phase-oncology-clinical-trials-unit-opened-at-mater-medical-independent 2024-10-14T13:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-phase-oncology-clinical-trials-unit-opened-at-mater-medical-independent 2024-10-14T13:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-research-milestone-in-billings-means-hope-for-montana-residents 2024-10-14T13:05:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-research-milestone-in-billings-means-hope-for-montana-residents 2024-10-14T13:05:37+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-of-the-effects-of-postbiotic-supplementation-on-inflammation-oxidative-stress 2024-10-14T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-of-the-effects-of-postbiotic-supplementation-on-inflammation-oxidative-stress 2024-10-14T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/nexalin-technology-appoints-carolyn-shelton-as-senior-vice-globenewswire 2024-10-14T12:55:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nexalin-technology-appoints-carolyn-shelton-as-senior-vice-globenewswire 2024-10-14T12:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/halia-therapeutics-to-participate-in-panel-at-bio-investor-forum-2024-kilgore-news-herald 2024-10-14T12:42:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halia-therapeutics-to-participate-in-panel-at-bio-investor-forum-2024-kilgore-news-herald 2024-10-14T12:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-biomarker-and-modeling-approach-to-support-dose-finding-for-bi-836880-a 2024-10-14T12:31:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-biomarker-and-modeling-approach-to-support-dose-finding-for-bi-836880-a 2024-10-14T12:31:41+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-reports-one-year-histologic-outcomes-in-phase-3-study-of-mirikizumab-compared-to 2024-10-14T12:26:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-reports-one-year-histologic-outcomes-in-phase-3-study-of-mirikizumab-compared-to 2024-10-14T12:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/belite-bio-announces-presentations-at-the-american-academy-of-ophthalmology-2024 2024-10-14T12:26:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belite-bio-announces-presentations-at-the-american-academy-of-ophthalmology-2024 2024-10-14T12:26:07+00:00 weekly 0.7 https://trial.medpath.com/news/cepi-to-initiate-phase-ii-trials-of-a-rift-valley-fever-vaccine-in-kenya 2024-10-14T12:19:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cepi-to-initiate-phase-ii-trials-of-a-rift-valley-fever-vaccine-in-kenya 2024-10-14T12:19:32+00:00 weekly 0.7 https://trial.medpath.com/news/spyre-therapeutics-announces-expected-acceleration-of-spy003-il-23p19-markets-data 2024-10-14T12:17:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spyre-therapeutics-announces-expected-acceleration-of-spy003-il-23p19-markets-data 2024-10-14T12:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/national-medical-products-administration-accepts-grand-pharmaceutical-group-limited-s 2024-10-14T12:13:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/national-medical-products-administration-accepts-grand-pharmaceutical-group-limited-s 2024-10-14T12:13:21+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-shows-efficacy-safety-of-car-t-cell-therapy-in-r-r-mantle-cell-lymphoma 2024-10-14T12:07:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-shows-efficacy-safety-of-car-t-cell-therapy-in-r-r-mantle-cell-lymphoma 2024-10-14T12:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/global-protac-therapy-market-clinical-trials-drug-approval-insight 2024-10-14T12:07:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-protac-therapy-market-clinical-trials-drug-approval-insight 2024-10-14T12:07:38+00:00 weekly 0.7 https://trial.medpath.com/news/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m11d1-in-relapsed 2024-10-14T12:05:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m11d1-in-relapsed 2024-10-14T12:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-data-supports-the-long-term-safety-of-sts101-for-acute-treatment-of-migraine 2024-10-14T12:04:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-data-supports-the-long-term-safety-of-sts101-for-acute-treatment-of-migraine 2024-10-14T12:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-makes-2-6b-cash-move-for-longboard-a-month-after-starting-phase-3-in-dravet-syndrome 2024-10-14T11:25:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lundbeck-makes-2-6b-cash-move-for-longboard-a-month-after-starting-phase-3-in-dravet-syndrome 2024-10-14T11:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/non-viral-crispr-therapy-alleviates-symptoms-in-humanised-mouse-model-of-primary 2024-10-14T11:24:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-viral-crispr-therapy-alleviates-symptoms-in-humanised-mouse-model-of-primary 2024-10-14T11:24:33+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-on-cervical-cancer-treatment-could-cut-deaths-by-40 2024-10-14T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-on-cervical-cancer-treatment-could-cut-deaths-by-40 2024-10-14T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/redhill-biopharma-secures-u-s-government-funding-through-barda-to-advance-stock-titan 2024-10-14T11:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/redhill-biopharma-secures-u-s-government-funding-through-barda-to-advance-stock-titan 2024-10-14T11:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/bausch-lomb-receives-fda-approval-for-envista-r-envytm-full-range-of-vision-intraocular-lens 2024-10-14T11:08:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bausch-lomb-receives-fda-approval-for-envista-r-envytm-full-range-of-vision-intraocular-lens 2024-10-14T11:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-plus-intestinal-zap-therapy-may-eliminate-need-for-insulin-in-type-2-diabetics 2024-10-14T10:06:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-plus-intestinal-zap-therapy-may-eliminate-need-for-insulin-in-type-2-diabetics 2024-10-14T10:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/mater-research-initiates-combined-covid-flu-vaccine-trial 2024-10-14T10:00:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mater-research-initiates-combined-covid-flu-vaccine-trial 2024-10-14T10:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-enhanced-provider-payer-collaboration-to-transform-value-based-oncology-care 2024-10-14T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-call-for-enhanced-provider-payer-collaboration-to-transform-value-based-oncology-care 2024-10-14T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-antibody-drug-conjugates-market-opportunity-globenewswire 2024-10-14T09:57:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bispecific-antibody-drug-conjugates-market-opportunity-globenewswire 2024-10-14T09:57:38+00:00 weekly 0.7 https://trial.medpath.com/news/stgen-bio-secures-fda-cgmp-approval-for-songdo-bio-plant-komedidaskeom 2024-10-14T09:56:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stgen-bio-secures-fda-cgmp-approval-for-songdo-bio-plant-komedidaskeom 2024-10-14T09:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/iteos-awaits-non-small-cell-lung-cancer-trial-data 2024-10-14T09:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iteos-awaits-non-small-cell-lung-cancer-trial-data 2024-10-14T09:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-applies-for-eu-approval-of-prostate-cancer-drug-for-another-indication 2024-10-14T09:09:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-applies-for-eu-approval-of-prostate-cancer-drug-for-another-indication 2024-10-14T09:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-share-price-falls-after-phase-ii-failure-marketscreener 2024-10-14T08:15:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transgene-share-price-falls-after-phase-ii-failure-marketscreener 2024-10-14T08:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-reports-positive-results-from-depemokimab-trial-research-the-market-halifax 2024-10-14T07:55:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-reports-positive-results-from-depemokimab-trial-research-the-market-halifax 2024-10-14T07:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/turnstone-biologics-announces-strategic-restructuring-to-prioritize-portfolio-and-extend 2024-10-14T07:12:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/turnstone-biologics-announces-strategic-restructuring-to-prioritize-portfolio-and-extend 2024-10-14T07:12:52+00:00 weekly 0.7 https://trial.medpath.com/news/paradigm-shift-in-rare-cancer-research-biomarker-driven-approach-reshapes-oncology-landscape 2024-10-14T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paradigm-shift-in-rare-cancer-research-biomarker-driven-approach-reshapes-oncology-landscape 2024-10-14T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-faces-336m-waste-from-lecanemab-vial-sizes-in-alzheimer-s-treatment 2024-10-14T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicare-faces-336m-waste-from-lecanemab-vial-sizes-in-alzheimer-s-treatment 2024-10-14T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-announces-filing-of-2024-half-year-report-conditions-for-accessing-or 2024-10-14T06:59:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inventiva-announces-filing-of-2024-half-year-report-conditions-for-accessing-or 2024-10-14T06:59:53+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-hails-phase-iii-nasal-polyps-success-proactive-investors 2024-10-14T06:54:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-hails-phase-iii-nasal-polyps-success-proactive-investors 2024-10-14T06:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-highlights-precision-medicine-approach-for-type-1-diabetes-at-the-cision-news 2024-10-14T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-highlights-precision-medicine-approach-for-type-1-diabetes-at-the-cision-news 2024-10-14T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-announces-financing-of-up-to-eur348-million-to-advance-the-nativ3-phase-3-mash-study 2024-10-14T06:33:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inventiva-announces-financing-of-up-to-eur348-million-to-advance-the-nativ3-phase-3-mash-study 2024-10-14T06:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-provides-update-on-phase-ii-trial-of-therapeutic-cancer-vaccine-tg4001-in 2024-10-14T06:22:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transgene-provides-update-on-phase-ii-trial-of-therapeutic-cancer-vaccine-tg4001-in 2024-10-14T06:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-announces-positive-phase-iii-results-from-anchor-trials-for-depemokimab-in-chronic 2024-10-14T06:08:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-announces-positive-phase-iii-results-from-anchor-trials-for-depemokimab-in-chronic 2024-10-14T06:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-experts-address-cannabis-use-in-cancer-care-and-rising-drug-cost-challenges 2024-10-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-experts-address-cannabis-use-in-cancer-care-and-rising-drug-cost-challenges 2024-10-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-and-safety-of-azvudine-versus-nirmatrelvir-ritonavir-in-adult-patients-infected 2024-10-14T05:40:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effectiveness-and-safety-of-azvudine-versus-nirmatrelvir-ritonavir-in-adult-patients-infected 2024-10-14T05:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/nicox-and-soleus-sign-16-5-million-royalty-and-equity-financing 2024-10-14T05:31:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nicox-and-soleus-sign-16-5-million-royalty-and-equity-financing 2024-10-14T05:31:59+00:00 weekly 0.7 https://trial.medpath.com/news/data-driven-omnichannel-strategy-revolutionizes-healthcare-professional-engagement-in-pharma 2024-10-14T05:17:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-driven-omnichannel-strategy-revolutionizes-healthcare-professional-engagement-in-pharma 2024-10-14T05:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-receives-u-s-fda-approval-for-320-mg-single-injection-device-presentations-of 2024-10-14T05:14:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-receives-u-s-fda-approval-for-320-mg-single-injection-device-presentations-of 2024-10-14T05:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/majority-of-children-with-spinal-muscular-atrophy-sma-globenewswire 2024-10-14T05:04:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/majority-of-children-with-spinal-muscular-atrophy-sma-globenewswire 2024-10-14T05:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/breast-neurotization-a-breakthrough-technique-to-restore-post-mastectomy-sensation 2024-10-14T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breast-neurotization-a-breakthrough-technique-to-restore-post-mastectomy-sensation 2024-10-14T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cenyx-biotech-scores-nod-for-us-phase-1-trial-for-subarachnoid-hemorrhage-drug-kbr 2024-10-14T04:44:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cenyx-biotech-scores-nod-for-us-phase-1-trial-for-subarachnoid-hemorrhage-drug-kbr 2024-10-14T04:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/ai-poised-to-transform-pharmaceutical-industry-with-208-billion-investment-by-2030 2024-10-14T04:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-poised-to-transform-pharmaceutical-industry-with-208-billion-investment-by-2030 2024-10-14T04:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-amgen-camurus-iterum-and-lexicon-biospace 2024-10-14T04:08:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-amgen-camurus-iterum-and-lexicon-biospace 2024-10-14T04:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/5-accelerated-approvals-gone-wrong-biospace 2024-10-14T04:08:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-accelerated-approvals-gone-wrong-biospace 2024-10-14T04:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/with-myriad-recent-approvals-in-cancer-the-era-of-bispecifics-is-here-biospace 2024-10-14T04:08:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-myriad-recent-approvals-in-cancer-the-era-of-bispecifics-is-here-biospace 2024-10-14T04:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-endoscopic-ultrasound-guided-celiac-plexus-block-on-the-palliation-of-pain-in-trials 2024-10-14T03:30:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-endoscopic-ultrasound-guided-celiac-plexus-block-on-the-palliation-of-pain-in-trials 2024-10-14T03:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/imricor-eyes-worldwide-expansion-with-progress-on-us-and-eu-regulatory-approval 2024-10-14T03:27:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imricor-eyes-worldwide-expansion-with-progress-on-us-and-eu-regulatory-approval 2024-10-14T03:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/dual-drug-combo-potential-breakthrough-for-dementia-mirage-news 2024-10-14T03:24:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dual-drug-combo-potential-breakthrough-for-dementia-mirage-news 2024-10-14T03:24:06+00:00 weekly 0.7 https://trial.medpath.com/news/24-months-clinical-prospective-of-proximal-restorations-with-repeated-preheating-bulk-fill 2024-10-14T02:54:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/24-months-clinical-prospective-of-proximal-restorations-with-repeated-preheating-bulk-fill 2024-10-14T02:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/daewoong-pharmaceutical-s-diabetes-drug-wins-approval-in-ecuador-pulse 2024-10-14T02:29:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daewoong-pharmaceutical-s-diabetes-drug-wins-approval-in-ecuador-pulse 2024-10-14T02:29:36+00:00 weekly 0.7 https://trial.medpath.com/news/immuno-oncology-is-a-treatment-that-strengthens-the-immune-system-that-attacks-cancer-cells-it-effe 2024-10-14T02:29:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuno-oncology-is-a-treatment-that-strengthens-the-immune-system-that-attacks-cancer-cells-it-effe 2024-10-14T02:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-analysis-of-haic-combined-with-lenvatinib-plus-pd1-inhibitor-vs-first-line-systemic 2024-10-14T01:54:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-analysis-of-haic-combined-with-lenvatinib-plus-pd1-inhibitor-vs-first-line-systemic 2024-10-14T01:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/privacy-friendly-evaluation-of-patient-data-with-secure-multiparty-computation-in-a-nature 2024-10-14T01:44:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/privacy-friendly-evaluation-of-patient-data-with-secure-multiparty-computation-in-a-nature 2024-10-14T01:44:06+00:00 weekly 0.7 https://trial.medpath.com/news/shanghai-s-science-ecosystem-powers-pharma-giants-innovation-shine-news 2024-10-14T01:11:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shanghai-s-science-ecosystem-powers-pharma-giants-innovation-shine-news 2024-10-14T01:11:46+00:00 weekly 0.7 https://trial.medpath.com/news/guangzhou-baiyunshan-s-generic-drug-wins-approval-tipranks-com 2024-10-14T01:10:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guangzhou-baiyunshan-s-generic-drug-wins-approval-tipranks-com 2024-10-14T01:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-trial-stem-cells-to-cure-blindness-in-animals-bond-university 2024-10-14T01:00:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-trial-stem-cells-to-cure-blindness-in-animals-bond-university 2024-10-14T01:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/digital-technologies-transform-cognitive-assessment-in-schizophrenia-drug-trials 2024-10-14T00:52:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-technologies-transform-cognitive-assessment-in-schizophrenia-drug-trials 2024-10-14T00:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/ssy-group-s-muscle-relaxant-drug-secures-china-approval-tipranks-com 2024-10-14T00:17:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ssy-group-s-muscle-relaxant-drug-secures-china-approval-tipranks-com 2024-10-14T00:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/aptamer-drug-conjugates-loaded-bacteria-for-pancreatic-cancer-synergistic-therapy-nature 2024-10-14T00:08:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aptamer-drug-conjugates-loaded-bacteria-for-pancreatic-cancer-synergistic-therapy-nature 2024-10-14T00:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/ux111-for-sanfilippo-syndrome-type-a-mps-iiia-ultragenyx 2024-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ux111-for-sanfilippo-syndrome-type-a-mps-iiia-ultragenyx 2024-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pacritinib-response-is-associated-with-overall-survival-in 2024-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pacritinib-response-is-associated-with-overall-survival-in 2024-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-pharma-shares-lift-on-clinical-trial-and-new-ceo-capital-brief 2024-10-13T23:51:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarity-pharma-shares-lift-on-clinical-trial-and-new-ceo-capital-brief 2024-10-13T23:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-oxytocin-receptor-agonists-on-hair-growth-promotion-scientific-reports-nature 2024-10-13T23:39:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effects-of-oxytocin-receptor-agonists-on-hair-growth-promotion-scientific-reports-nature 2024-10-13T23:39:21+00:00 weekly 0.7 https://trial.medpath.com/news/new-trials-into-benefits-of-cannabis-based-medicine-for-children-with-epilepsy-belfast-live 2024-10-13T23:12:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-trials-into-benefits-of-cannabis-based-medicine-for-children-with-epilepsy-belfast-live 2024-10-13T23:12:21+00:00 weekly 0.7 https://trial.medpath.com/news/children-with-aggressive-blood-cancer-offered-treatment-cure-hope-the-independent 2024-10-13T23:10:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/children-with-aggressive-blood-cancer-offered-treatment-cure-hope-the-independent 2024-10-13T23:10:59+00:00 weekly 0.7 https://trial.medpath.com/news/boy-has-300-seizures-a-day-until-he-takes-medical-cannabis-now-there-s-hope-for-others 2024-10-13T21:32:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boy-has-300-seizures-a-day-until-he-takes-medical-cannabis-now-there-s-hope-for-others 2024-10-13T21:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/ngs-technology-advances-promise-to-transform-precision-oncology-trial-recruitment-and-diversity 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ngs-technology-advances-promise-to-transform-precision-oncology-trial-recruitment-and-diversity 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-outcome-assessments-a-critical-foundation-for-modern-drug-development-success 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-outcome-assessments-a-critical-foundation-for-modern-drug-development-success 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-hub-partner-selection-critical-for-successful-drug-launch-and-patient-support 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strategic-hub-partner-selection-critical-for-successful-drug-launch-and-patient-support 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tvtx-investor-alert-bronstein-gewirtz-and-grossman-llc-globenewswire 2024-10-13T20:21:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tvtx-investor-alert-bronstein-gewirtz-and-grossman-llc-globenewswire 2024-10-13T20:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/blinklab-asx-bb1-is-this-exciting-company-the-next-resapp-stocks-down-under 2024-10-13T19:21:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blinklab-asx-bb1-is-this-exciting-company-the-next-resapp-stocks-down-under 2024-10-13T19:21:53+00:00 weekly 0.7 https://trial.medpath.com/news/her2-positive-treatment-resistant-breast-cancer-treatment-breakthrough-hmri 2024-10-13T17:39:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/her2-positive-treatment-resistant-breast-cancer-treatment-breakthrough-hmri 2024-10-13T17:39:15+00:00 weekly 0.7 https://trial.medpath.com/news/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy 2024-10-13T16:52:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy 2024-10-13T16:52:50+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-breakthrough-new-miracle-treatment-yields-remarkable-results-this-could-be-the-cure 2024-10-13T16:30:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-breakthrough-new-miracle-treatment-yields-remarkable-results-this-could-be-the-cure 2024-10-13T16:30:33+00:00 weekly 0.7 https://trial.medpath.com/news/startups-are-biohacking-psychedelic-drugs-to-make-sure-you-never-have-a-bad-trip-again 2024-10-13T16:08:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/startups-are-biohacking-psychedelic-drugs-to-make-sure-you-never-have-a-bad-trip-again 2024-10-13T16:08:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gets-drugs-out-faster-but-some-work-only-marginally-better-and-are-more-expensive 2024-10-13T14:30:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-gets-drugs-out-faster-but-some-work-only-marginally-better-and-are-more-expensive 2024-10-13T14:30:32+00:00 weekly 0.7 https://trial.medpath.com/news/prostate-cancer-holy-grail-spit-test-could-save-nhs-ps500m-every-year-express-co-uk 2024-10-13T14:24:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prostate-cancer-holy-grail-spit-test-could-save-nhs-ps500m-every-year-express-co-uk 2024-10-13T14:24:21+00:00 weekly 0.7 https://trial.medpath.com/news/internet-based-cognitive-behavioral-intervention-for-adolescents-with-anxiety-disorders-trials 2024-10-13T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/internet-based-cognitive-behavioral-intervention-for-adolescents-with-anxiety-disorders-trials 2024-10-13T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/point-of-care-hepatitis-c-test-may-expedite-diagnosis-contagion-live 2024-10-13T13:35:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/point-of-care-hepatitis-c-test-may-expedite-diagnosis-contagion-live 2024-10-13T13:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-secures-250-million-usd-to-propel-global-expansion-of-its-innovative-drug-pipeline 2024-10-13T13:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-secures-250-million-usd-to-propel-global-expansion-of-its-innovative-drug-pipeline 2024-10-13T13:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/gammora-breakthrough-hiv-treatment-to-be-presented-at-international-conferences 2024-10-13T13:17:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gammora-breakthrough-hiv-treatment-to-be-presented-at-international-conferences 2024-10-13T13:17:17+00:00 weekly 0.7 https://trial.medpath.com/news/junshi-biosciences-ongericimab-wins-drug-approval-tipranks-com 2024-10-13T11:07:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/junshi-biosciences-ongericimab-wins-drug-approval-tipranks-com 2024-10-13T11:07:54+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-uncover-essential-developments-in-breast-cancer-multiple-myeloma 2024-10-13T11:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-targeted-pulse-uncover-essential-developments-in-breast-cancer-multiple-myeloma 2024-10-13T11:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/nanoscope-therapeutics-inc-acquires-a-license-for-the-catch-technology-modern-retina 2024-10-13T10:16:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoscope-therapeutics-inc-acquires-a-license-for-the-catch-technology-modern-retina 2024-10-13T10:16:17+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-high-prevalence-of-fibromyalgia-in-post-covid-musculoskeletal-pain-patients 2024-10-13T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-high-prevalence-of-fibromyalgia-in-post-covid-musculoskeletal-pain-patients 2024-10-13T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sunvozertinib-granted-breakthrough-therapy-designation-by-china-cde-for-the-first-line 2024-10-13T08:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sunvozertinib-granted-breakthrough-therapy-designation-by-china-cde-for-the-first-line 2024-10-13T08:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/ftc-takes-legal-action-against-top-pbms-over-insulin-pricing-practices 2024-10-13T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ftc-takes-legal-action-against-top-pbms-over-insulin-pricing-practices 2024-10-13T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/data-presented-from-the-phase-1b-clinical-trial-evaluating-low-dose-lti-03-in-idiopathic-pulmonary-fibrosis 2024-10-13T04:10:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-presented-from-the-phase-1b-clinical-trial-evaluating-low-dose-lti-03-in-idiopathic-pulmonary-fibrosis 2024-10-13T04:10:21+00:00 weekly 0.7 https://trial.medpath.com/news/secukinumab-adalimumab-have-distinct-advantages-for-treating-psa-hcplive 2024-10-13T03:04:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/secukinumab-adalimumab-have-distinct-advantages-for-treating-psa-hcplive 2024-10-13T03:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/exact-sciences-launches-cologuard-plus-for-enhanced-colorectal-cancer-screening-in-adults-45-and-older 2024-10-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exact-sciences-launches-cologuard-plus-for-enhanced-colorectal-cancer-screening-in-adults-45-and-older 2024-10-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-regimen-could-improve-outcomes-in-transplantation-from-half-matched-donors 2024-10-13T01:36:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-regimen-could-improve-outcomes-in-transplantation-from-half-matched-donors 2024-10-13T01:36:54+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-that-means-most-lethal-cancer-is-a-death-sentence-no-more-how-miracle-drug 2024-10-13T01:27:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-that-means-most-lethal-cancer-is-a-death-sentence-no-more-how-miracle-drug 2024-10-13T01:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-indication-for-navidea-s-lymphatic-mapping-agent-rttnews 2024-10-12T22:36:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-indication-for-navidea-s-lymphatic-mapping-agent-rttnews 2024-10-12T22:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/iv-secukinumab-rapidly-improved-clinical-responses-in-psoriatic-arthritis-hcplive 2024-10-12T21:01:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iv-secukinumab-rapidly-improved-clinical-responses-in-psoriatic-arthritis-hcplive 2024-10-12T21:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-to-reconsider-decision-barring-compounded-versions-of-lilly-weight-loss-drug 2024-10-12T20:18:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-to-reconsider-decision-barring-compounded-versions-of-lilly-weight-loss-drug 2024-10-12T20:18:51+00:00 weekly 0.7 https://trial.medpath.com/news/scientific-advisory-committee-on-health-products-for-women-sac-hpw-canada-ca 2024-10-12T19:51:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scientific-advisory-committee-on-health-products-for-women-sac-hpw-canada-ca 2024-10-12T19:51:05+00:00 weekly 0.7 https://trial.medpath.com/news/2-biotech-stocks-that-are-screaming-buys-this-month 2024-10-12T17:59:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2-biotech-stocks-that-are-screaming-buys-this-month 2024-10-12T17:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/race-based-correction-in-pulmonary-function-testing-in-copd-research 2024-10-12T17:42:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/race-based-correction-in-pulmonary-function-testing-in-copd-research 2024-10-12T17:42:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-says-medtronic-can-study-affera-pulsed-field-ablation-system-for-treating-ventricular-tachycardia 2024-10-12T17:40:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-says-medtronic-can-study-affera-pulsed-field-ablation-system-for-treating-ventricular-tachycardia 2024-10-12T17:40:31+00:00 weekly 0.7 https://trial.medpath.com/news/why-were-so-few-randomized-trials-of-public-health-and-social-measures-conducted-during 2024-10-12T16:33:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-were-so-few-randomized-trials-of-public-health-and-social-measures-conducted-during 2024-10-12T16:33:21+00:00 weekly 0.7 https://trial.medpath.com/news/benitec-biopharma-reports-positive-data-from-two-subjects-globenewswire 2024-10-12T16:31:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benitec-biopharma-reports-positive-data-from-two-subjects-globenewswire 2024-10-12T16:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/7-year-old-paxton-in-remission-after-participating-in-new-cancer-drug-trial-at-ascension 2024-10-12T16:26:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/7-year-old-paxton-in-remission-after-participating-in-new-cancer-drug-trial-at-ascension 2024-10-12T16:26:49+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-new-pill-cuts-alcohol-consumption-by-over-50-the-brighter-side-of-news 2024-10-12T16:23:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-new-pill-cuts-alcohol-consumption-by-over-50-the-brighter-side-of-news 2024-10-12T16:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/thyme-care-appoints-value-based-care-expert-dr-lalan-wilfong-to-lead-oncology-transformation 2024-10-12T14:35:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thyme-care-appoints-value-based-care-expert-dr-lalan-wilfong-to-lead-oncology-transformation 2024-10-12T14:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/thyme-care-secures-95m-series-c-funding-to-transform-value-based-cancer-care-delivery 2024-10-12T13:54:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thyme-care-secures-95m-series-c-funding-to-transform-value-based-cancer-care-delivery 2024-10-12T13:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/neural-network-models-help-predict-immunotherapy-efficacy-in-small-cell-lung-cancer 2024-10-12T13:50:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neural-network-models-help-predict-immunotherapy-efficacy-in-small-cell-lung-cancer 2024-10-12T13:50:13+00:00 weekly 0.7 https://trial.medpath.com/news/corin-receives-fda-510-k-clearance-of-medial-constrained-tibial-insert-for-tka-healio 2024-10-12T13:37:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corin-receives-fda-510-k-clearance-of-medial-constrained-tibial-insert-for-tka-healio 2024-10-12T13:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/remote-ischemic-post-conditioning-for-neonatal-encephalopathy-a-safety-and-feasibility-trial 2024-10-12T13:27:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remote-ischemic-post-conditioning-for-neonatal-encephalopathy-a-safety-and-feasibility-trial 2024-10-12T13:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/aileron-therapeutics-to-present-previously-announced-data-from-the-phase-1b-clinical-trial 2024-10-12T13:09:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aileron-therapeutics-to-present-previously-announced-data-from-the-phase-1b-clinical-trial 2024-10-12T13:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/cgrp-monoclonal-antibodies-not-more-effective-than-topiramate-or-botox-for-treating-migraine 2024-10-12T12:58:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgrp-monoclonal-antibodies-not-more-effective-than-topiramate-or-botox-for-treating-migraine 2024-10-12T12:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/study-identifies-genetic-factors-crucial-in-acute-myeloid-leukemia-survival-for-black-patients 2024-10-12T12:14:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-identifies-genetic-factors-crucial-in-acute-myeloid-leukemia-survival-for-black-patients 2024-10-12T12:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/fixed-duration-ibrutinib-venetoclax-elicits-meaningful-survival-benefit-in-high-risk-cll-sll 2024-10-12T11:24:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fixed-duration-ibrutinib-venetoclax-elicits-meaningful-survival-benefit-in-high-risk-cll-sll 2024-10-12T11:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/home-blood-pressure-lowering-effect-of-esaxerenone-versus-trichlormethiazide-for-nature 2024-10-12T10:13:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/home-blood-pressure-lowering-effect-of-esaxerenone-versus-trichlormethiazide-for-nature 2024-10-12T10:13:22+00:00 weekly 0.7 https://trial.medpath.com/news/market-today-cvs-exits-infusion-services-tesla-s-robot-controv-gurufocus 2024-10-12T10:03:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/market-today-cvs-exits-infusion-services-tesla-s-robot-controv-gurufocus 2024-10-12T10:03:21+00:00 weekly 0.7 https://trial.medpath.com/news/topiramate-pregabalin-reduce-headache-frequency-intensity-in-pediatric-migraine 2024-10-12T08:03:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/topiramate-pregabalin-reduce-headache-frequency-intensity-in-pediatric-migraine 2024-10-12T08:03:04+00:00 weekly 0.7 https://trial.medpath.com/news/the-origins-of-modern-surgery-radical-mastectomy-and-the-first-randomized-trials-in-breast-cancer 2024-10-12T07:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-origins-of-modern-surgery-radical-mastectomy-and-the-first-randomized-trials-in-breast-cancer 2024-10-12T07:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/tirbanibulin-demonstrates-efficacy-for-actinic-keratosis-in-larger-field-treatment 2024-10-12T07:15:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirbanibulin-demonstrates-efficacy-for-actinic-keratosis-in-larger-field-treatment 2024-10-12T07:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/hopa-president-highlights-evolution-and-challenges-for-women-in-pharmacy-leadership 2024-10-12T07:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hopa-president-highlights-evolution-and-challenges-for-women-in-pharmacy-leadership 2024-10-12T07:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/cisplatin-s-prevalence-in-bladder-cancer-falters-with-the-introduction-of-enfortumab-vedotin 2024-10-12T07:03:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cisplatin-s-prevalence-in-bladder-cancer-falters-with-the-introduction-of-enfortumab-vedotin 2024-10-12T07:03:56+00:00 weekly 0.7 https://trial.medpath.com/news/engineered-hsv-can-trigger-genetic-chain-reaction-rejigger-hsv-genes-during-co-infection 2024-10-12T04:32:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/engineered-hsv-can-trigger-genetic-chain-reaction-rejigger-hsv-genes-during-co-infection 2024-10-12T04:32:34+00:00 weekly 0.7 https://trial.medpath.com/news/biomarker-testing-critical-for-optimizing-early-stage-nsclc-treatment-decisions 2024-10-12T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarker-testing-critical-for-optimizing-early-stage-nsclc-treatment-decisions 2024-10-12T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/sareum-holdings-completes-gbp2-4-million-fundraise-to-boost-lead-asset 2024-10-12T03:09:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sareum-holdings-completes-gbp2-4-million-fundraise-to-boost-lead-asset 2024-10-12T03:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/new-therapeutic-strategy-offers-hope-for-treating-aggressive-triple-negative-breast-cancer 2024-10-12T02:24:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-therapeutic-strategy-offers-hope-for-treating-aggressive-triple-negative-breast-cancer 2024-10-12T02:24:01+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-personalization-is-poised-to-define-new-era-of-mcrc-therapy-onclive 2024-10-12T02:22:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatment-personalization-is-poised-to-define-new-era-of-mcrc-therapy-onclive 2024-10-12T02:22:46+00:00 weekly 0.7 https://trial.medpath.com/news/upstream-raises-255m-ipo-for-inflammatory-drugs-camp4-nets-75m-for-rna-work 2024-10-12T02:21:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upstream-raises-255m-ipo-for-inflammatory-drugs-camp4-nets-75m-for-rna-work 2024-10-12T02:21:44+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-drug-could-be-used-to-save-the-limbs-of-peripheral-artery-disease-patients-pre 2024-10-12T01:39:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-drug-could-be-used-to-save-the-limbs-of-peripheral-artery-disease-patients-pre 2024-10-12T01:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-trial-surge-puts-the-focus-back-on-decentralisation-clinical-trials-arena 2024-10-12T01:33:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obesity-trial-surge-puts-the-focus-back-on-decentralisation-clinical-trials-arena 2024-10-12T01:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/mace-in-cv-trials-has-the-outcome-outlived-its-role-tctmd-com 2024-10-11T22:57:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mace-in-cv-trials-has-the-outcome-outlived-its-role-tctmd-com 2024-10-11T22:57:53+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-reports-third-quarter-fiscal-2024-financial-results-and-provides-a 2024-10-11T22:37:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-reports-third-quarter-fiscal-2024-financial-results-and-provides-a 2024-10-11T22:37:21+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-extends-partnership-with-keybioscience-pharmaceutical-executive 2024-10-11T22:03:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-extends-partnership-with-keybioscience-pharmaceutical-executive 2024-10-11T22:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/dr-wolf-on-challenges-conducting-clinical-trials-evaluating-surgery-in-mesothelioma 2024-10-11T21:08:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-wolf-on-challenges-conducting-clinical-trials-evaluating-surgery-in-mesothelioma 2024-10-11T21:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/tezepelumab-for-severe-asthma-improves-the-odds-of-a-good-night-s-sleep-medpage-today 2024-10-11T21:02:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezepelumab-for-severe-asthma-improves-the-odds-of-a-good-night-s-sleep-medpage-today 2024-10-11T21:02:20+00:00 weekly 0.7 https://trial.medpath.com/news/innocan-pharma-s-lpt-cbd-shows-long-term-success-in-relieving-osteoarthritis-pain-in-dogs 2024-10-11T20:59:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocan-pharma-s-lpt-cbd-shows-long-term-success-in-relieving-osteoarthritis-pain-in-dogs 2024-10-11T20:59:47+00:00 weekly 0.7 https://trial.medpath.com/news/bellaseno-s-clinical-trial-on-3d-printed-breast-implants-shows-promising-early-results 2024-10-11T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bellaseno-s-clinical-trial-on-3d-printed-breast-implants-shows-promising-early-results 2024-10-11T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-discontinues-denali-partnered-ms-trial-after-phase-2-failure-endpoints-news 2024-10-11T20:42:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-discontinues-denali-partnered-ms-trial-after-phase-2-failure-endpoints-news 2024-10-11T20:42:49+00:00 weekly 0.7 https://trial.medpath.com/news/safety-data-favor-diuretic-strategy-triggered-by-cardiac-monitoring-alerts-in-hf 2024-10-11T20:26:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-data-favor-diuretic-strategy-triggered-by-cardiac-monitoring-alerts-in-hf 2024-10-11T20:26:49+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-at-fda-new-dscsa-exemptions-hemophilia-prophylactic-approved-and-more 2024-10-11T20:22:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-week-at-fda-new-dscsa-exemptions-hemophilia-prophylactic-approved-and-more 2024-10-11T20:22:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-single-dose-intravenous-paclitaxel-biosimilar-for-breast-cancer-onclive 2024-10-11T20:18:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-single-dose-intravenous-paclitaxel-biosimilar-for-breast-cancer-onclive 2024-10-11T20:18:06+00:00 weekly 0.7 https://trial.medpath.com/news/pa-psychedelic-bulletin-176-drug-developers-discuss-trial-design-massachusetts-vote 2024-10-11T20:01:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pa-psychedelic-bulletin-176-drug-developers-discuss-trial-design-massachusetts-vote 2024-10-11T20:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/norstella-introduces-a-fully-integrated-data-asset-for-biopharma 2024-10-11T19:07:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/norstella-introduces-a-fully-integrated-data-asset-for-biopharma 2024-10-11T19:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-secures-fda-approval-for-inavolisib-in-advanced-hr-her2-breast-cancer 2024-10-11T19:06:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genentech-secures-fda-approval-for-inavolisib-in-advanced-hr-her2-breast-cancer 2024-10-11T19:06:00+00:00 weekly 0.7